US20200109448A1 - Labelled nucleotides - Google Patents
Labelled nucleotides Download PDFInfo
- Publication number
- US20200109448A1 US20200109448A1 US16/593,512 US201916593512A US2020109448A1 US 20200109448 A1 US20200109448 A1 US 20200109448A1 US 201916593512 A US201916593512 A US 201916593512A US 2020109448 A1 US2020109448 A1 US 2020109448A1
- Authority
- US
- United States
- Prior art keywords
- nucleotide
- nucleotides
- detectable label
- linker
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RGXUUMKKMMUMJS-UHFFFAOYSA-K C.C.C.C1=CN=C(SSC2=NC=CC=C2)C=C1.CC(C)(C)OC(=O)NCCS.CC(C)(C)OC(=O)NCCSSC1=NC=CC=C1.CC(C)(C)OC(=O)NCCSSC1=NC=CC=C1.CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSC3=CC=CC=N3)C=C1)=C1C=CC(=N(C)C)C=C1O2.CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCC(=O)NCC#CC3=CN(C4CC(O)C(CPPP=O)O4)C(=O)NC3=O)C=C1)=C1C=CC(=N(C)C)C=C1O2.CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCOC=O)C=C1)=C1C=CC(=N(C)C)C=C1O2.NCC#CC1=CN(C2CC(O)C(CPPP=O)O2)C(=O)NC1=O.O=COCCS Chemical compound C.C.C.C1=CN=C(SSC2=NC=CC=C2)C=C1.CC(C)(C)OC(=O)NCCS.CC(C)(C)OC(=O)NCCSSC1=NC=CC=C1.CC(C)(C)OC(=O)NCCSSC1=NC=CC=C1.CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSC3=CC=CC=N3)C=C1)=C1C=CC(=N(C)C)C=C1O2.CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCC(=O)NCC#CC3=CN(C4CC(O)C(CPPP=O)O4)C(=O)NC3=O)C=C1)=C1C=CC(=N(C)C)C=C1O2.CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCOC=O)C=C1)=C1C=CC(=N(C)C)C=C1O2.NCC#CC1=CN(C2CC(O)C(CPPP=O)O2)C(=O)NC1=O.O=COCCS RGXUUMKKMMUMJS-UHFFFAOYSA-K 0.000 description 1
- OGGAHPIWHJRTEC-UHFFFAOYSA-L CCN(CC1=CN(CC(=O)NCCCC(=O)C2=CC=C(C3=C4C=CC(=[N+](C)C)C=C4OC4=C3C=CC(N(C)C)=C4)C(C(=O)[O-])=C2)C2=C1C=CC=C2)C(=O)CCC(=O)CCC#CC1=CN(C2CC(O)C(COP(=O)([O-])OP(=O)([O-])OP(=O)(O)O)O2)C(=O)CC1=O Chemical compound CCN(CC1=CN(CC(=O)NCCCC(=O)C2=CC=C(C3=C4C=CC(=[N+](C)C)C=C4OC4=C3C=CC(N(C)C)=C4)C(C(=O)[O-])=C2)C2=C1C=CC=C2)C(=O)CCC(=O)CCC#CC1=CN(C2CC(O)C(COP(=O)([O-])OP(=O)([O-])OP(=O)(O)O)O2)C(=O)CC1=O OGGAHPIWHJRTEC-UHFFFAOYSA-L 0.000 description 1
- VDWZZDDOFIXTFK-UHFFFAOYSA-N CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSC3=CC=CC=N3)C=C1)=C1C=CC(=[N+](C)C)C=C1O2 Chemical compound CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSC3=CC=CC=N3)C=C1)=C1C=CC(=[N+](C)C)C=C1O2 VDWZZDDOFIXTFK-UHFFFAOYSA-N 0.000 description 1
- USZXZXZGOOKGQO-UHFFFAOYSA-N CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCC(=O)NCC#CC3=CN(C4CC(O)C(CPPP=O)O4)C(=O)NC3=O)C=C1)=C1C=CC(=[N+](C)C)C=C1O2 Chemical compound CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCC(=O)NCC#CC3=CN(C4CC(O)C(CPPP=O)O4)C(=O)NC3=O)C=C1)=C1C=CC(=[N+](C)C)C=C1O2 USZXZXZGOOKGQO-UHFFFAOYSA-N 0.000 description 1
- OYWLJOXRLFPZLL-UHFFFAOYSA-N CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCOC=O)C=C1)=C1C=CC(=[N+](C)C)C=C1O2 Chemical compound CN(C)C1=CC2=C(C=C1)C(C1=C(C(=O)[O-])C=C(C(=O)NCCSSCCOC=O)C=C1)=C1C=CC(=[N+](C)C)C=C1O2 OYWLJOXRLFPZLL-UHFFFAOYSA-N 0.000 description 1
- FGZPIVHQMPJFSV-UHFFFAOYSA-L CN(C)C1=CC2=C(C=C1)C(C1=CC=C(C(=O)CCCNC(=O)CCCCOC3=CC4=C(C=C3)C(NC(=O)CCC(=O)CCC#CC3=CN(C5CC(O)C(COP(=O)([O-])OP(=O)([O-])OP(=O)(O)O)O5)C(=O)CC3=O)C3=CC=CC=C3O4)C=C1C(=O)[O-])=C1C=CC(=[N+](C)C)C=C1O2 Chemical compound CN(C)C1=CC2=C(C=C1)C(C1=CC=C(C(=O)CCCNC(=O)CCCCOC3=CC4=C(C=C3)C(NC(=O)CCC(=O)CCC#CC3=CN(C5CC(O)C(COP(=O)([O-])OP(=O)([O-])OP(=O)(O)O)O5)C(=O)CC3=O)C3=CC=CC=C3O4)C=C1C(=O)[O-])=C1C=CC(=[N+](C)C)C=C1O2 FGZPIVHQMPJFSV-UHFFFAOYSA-L 0.000 description 1
- LAMOTWGIXJPPHW-UHFFFAOYSA-N CN(C)C1=CC2=C(C=C1)C(C1=CC=C(C(=O)CCCNC(=O)CCCCOC3=CC4=C(C=C3)C(NC(=O)CCC(=O)O)C3=CC=CC=C3O4)C=C1C(=O)[O-])=C1C=CC(=[N+](C)C)C=C1O2 Chemical compound CN(C)C1=CC2=C(C=C1)C(C1=CC=C(C(=O)CCCNC(=O)CCCCOC3=CC4=C(C=C3)C(NC(=O)CCC(=O)O)C3=CC=CC=C3O4)C=C1C(=O)[O-])=C1C=CC(=[N+](C)C)C=C1O2 LAMOTWGIXJPPHW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6823—Release of bound markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/186—Modifications characterised by incorporating a non-extendable or blocking moiety
Definitions
- the present application includes a sequence listing in Electronic format.
- the Sequence Listing is provided as a file entitled “ILLINC371D3 sequence listing.txt”, which is approximately 824 bytes in size.
- the information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
- This invention relates to labelled nucleotides.
- this invention discloses nucleotides having a removable label and their use in polynucleotide sequencing methods.
- nucleic acids An example of the technologies that have improved the study of nucleic acids, is the development of fabricated arrays of immobilised nucleic acids. These arrays consist typically of a high-density matrix of polynucleotides immobilised onto a solid support material. See, e.g., Fodor et al., Trends Biotech. 12:19-26, 1994, which describes ways of assembling the nucleic acids using a chemically sensitized glass surface protected by a mask, but exposed at defined areas to allow attachment of suitably modified nucleotide phosphoramidites.
- Fabricated arrays can also be manufactured by the technique of “spotting” known polynucleotides onto a solid support at predetermined positions (e.g., Stimpson et al., Proc. Natl. Acad. Sci. USA 92:6379-6383, 1995).
- array technology is the attachment of the polynucleotides to the solid support material to form single molecule arrays.
- Arrays of this type are disclosed in International Patent App. WO 00/06770. The advantage of these arrays is that reactions can be monitored at the single molecule level and information on large numbers of single molecules can be collated from a single reaction.
- a nucleoside or nucleotide molecule is linked to a detectable label via a cleavable linker group attached to the base, rendering the molecule useful in techniques using Labelled nucleosides or nucleotides, e.g., sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridization assays, single nucleotide polymorphism studies, and other techniques using enzymes such as polymerases, reverse transcriptases, terminal transferases, or other DNA modifying enzymes.
- Labelled nucleosides or nucleotides e.g., sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridization assays, single nucleotide polymorphism studies, and other techniques using enzymes such as polymerases, reverse transcriptases, terminal transferases, or other DNA modifying enzymes.
- the invention is especially useful in techniques that use Labelled dNTPs, such as nick translation, random primer labeling, end-labeling (e.g., with terminal deoxynucleotidyltransferase), reverse transcription, or nucleic acid amplification.
- Labelled dNTPs such as nick translation, random primer labeling, end-labeling (e.g., with terminal deoxynucleotidyltransferase), reverse transcription, or nucleic acid amplification.
- the molecules of the present invention are in contrast to the prior art, where the label is attached to the ribose or deoxyribose sugar, or where the label is attached via a non-cleavable linker.
- a nucleotide or nucleoside molecule has a base that is linked to a detectable label via a cleavable linker.
- the invention features a nucleotide or nucleoside molecule, having a base that is linked to a detectable label via a cleavable linker.
- the base can be a purine, or a pyrimidine.
- the base can be a deazapurine.
- the molecule can have a ribose or deoxyribose sugar moiety.
- the ribose or deoxyribose sugar can include a protecting group attached via the 2′ or 3′ oxygen atom. The protecting group can be removed to expose a 3′-OH.
- the molecule can be a deoxyribonucleotide triphosphate.
- the detectable label can be a fluorophore.
- the linker can be an acid labile linker, a photolabile linker, or can contain a disulphide linkage.
- the invention also features a method of labeling a nucleic acid molecule, where the method includes incorporating into the nucleic acid molecule a nucleotide or nucleoside molecule, where the nucleotide or nucleoside molecule has a base that is linked to a detectable label via a cleavable linker.
- the incorporating step can be accomplished via a terminal transferase, a polymerase or a reverse transcriptase.
- the base can be a purine, or a pyrimidine.
- the base can be a deazapurine.
- the nucleotide or nucleoside molecule can have a ribose or deoxyribose sugar moiety.
- the ribose or deoxyribose sugar can include a protecting group attached via the 2′ or 3′ oxygen atom.
- the protecting group can be removed to expose a 3′-OH group.
- the molecule can be a deoxyribonucleotide triphosphate.
- the detectable label can be a fluorophore.
- the linker can be an acid labile linker, a photolabile linker, or can contain a disulphide linkage.
- the detectable label and/or the cleavable linker can be of a size sufficient to prevent the incorporation of a second nucleotide or nucleoside into the nucleic acid molecule.
- the invention features a method for determining the sequence of a target single-stranded polynucleotide, where the method includes monitoring the sequential incorporation of complementary nucleotides, where the nucleotides each have a base that is linked to a detectable label via a cleavable linker, and where the identity of each nucleotide incorporated is determined by detection of the label linked to the base, and subsequent removal of the label.
- the invention also features a method for determining the sequence of a target single-stranded polynucleotide, where the method includes: (a) providing nucleotides, where the nucleotides have a base that is linked to a detectable label via a cleavable linker, and where the detectable label linked to each type of nucleotide can be distinguished upon detection from the detectable label used for other types of nucleotides; (b) incorporating a nucleotide into the complement of the target single stranded polynucleotide; (c) detecting the label of the nucleotide of (b), thereby determining the type of nucleotide incorporated; (d) removing the label of the nucleotide of (b); and (e) optionally repeating steps (b)-(d) one or more times; thereby determining the sequence of a target single-stranded polynucleotide.
- each of the nucleotides can be brought into contact with thew target sequentially, with removal of non-incorporated nucleotides prior to addition of the next nucleotide, where detection and removal of the label is carried out either after addition of each nucleotide, or after addition of all four nucleotides.
- all of the nucleotides can be brought into contact with the target simultaneously, i.e., a composition comprising all of the different nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label(s).
- the methods can comprise a first step and a second step, where in the first step, a first composition comprising two of the four nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where in the second step, a second composition comprising the two nucleotides not included in the first composition is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where the first steps and the second step can be optionally repeated one or more times.
- the methods described herein can also comprise a first step and a second step, where in the first step, a composition comprising one of the four nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where in the second step, a second composition comprising the three nucleotides not included in the first composition is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where the first steps and the second step can be optionally repeated one or more times.
- the methods described herein can also comprise a first step and a second step, where in the first step, a first composition comprising three of the four nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where in the second step, a composition comprising the nucleotide not included in the first composition is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where the first steps and the second step can be optionally repeated one or more times.
- the invention features a kit, where the kit includes: (a) individual the nucleotides, where each nucleotide has a base that is linked to a detectable label via a cleavable linker, and where the detectable label linked to each nucleotide can be distinguished upon detection from the detectable label used for other three nucleotides; and (b) packaging materials therefor.
- the kit can further include an enzyme and buffers appropriate for the action of the enzyme.
- a method for determining the sequence of a target polynucleotide comprises monitoring the sequential incorporation of complementary nucleotides, wherein the nucleotides comprise a detectable label linked to the base portion of the nucleotide via a cleavable linker, incorporation is detected by monitoring the label, and the label is removed to permit further nucleotide incorporation to occur.
- FIG. 3 shows some functional molecules useful in the invention, including some cleavable linkers and some suitable hydroxyl protecting groups.
- R 1 and R 2 may be the same of different, and can be H, OH, or any group which can be transformed into an OH group, including a carbonyl.
- R 3 represents one or more substituents independently selected from alkyl, alkoxyl, amino or halogen groups.
- cleavable linkers may be constructed from any labile functionality used on the 3′-block.
- R 4 and R 5 can be H or alkyl, and R 6 can be alkyl, cycloalkyl, alkenyl, cycloalkenyl or benzyl.
- X can be H, phosphate, diphosphate or triphosphate.
- FIG. 4 shows a denaturing gel showing the incorporation of the triphosphate of Example 1 using Klenow polymerase.
- FIG. 5 shows a denaturing gel showing the incorporation of the triphosphate of Example 3 using Klenow polymerase.
- FIG. 6 shows a denaturing gel showing the incorporation of the triphosphate of Example 4 using Klenow polymerase.
- the present invention relates to nucleotides and nucleosides that are modified by attachment of a label via a cleavable linker, thereby rendering the molecule useful in techniques where the labelled molecule is to interact with an enzyme, such as sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridization assays, single nucleotide polymorphism studies, techniques using enzymes such as polymerase, reverse transcriptase, terminal transferase, techniques that use Labelled dNTPs (e.g., nick translation, random primer labeling, end-labeling (e.g., with terminal deoxynucleotidyltransferase), reverse transcription, or nucleic acid amplification).
- an enzyme such as sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridization assays, single nucleotide polymorphism studies, techniques using enzymes such as polymerase, reverse transcript
- the C-1 atom of deoxyribose is bonded to N-1 of a pyrimidine or N-9 of a purine.
- a nucleotide is also a phosphate ester of a nucleoside, with esterification occurring on the hydroxyl group attached to C-5 of the sugar. Nucleotides are usually mono, di- or triphosphates.
- “Derivative” and “analog” also mean a synthetic nucleotide or nucleoside derivative having modified base moieties and/or modified sugar moieties. Such derivatives and analogs are discussed in, e.g., Scheit, Nucleotide Analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90:543-584, 1990. Nucleotide analogs can also comprise modified phosphodiester linkages, including phosphorothioate, phosphorodithioate, alkylphosphonate, phosphoranilidate and phosphoramidate linkages. The analogs should be capable of undergoing Watson-Crick base pairing. “Derivative” and “analog”, as used herein, may be used interchangeably, and are encompassed by the terms “nucleotide” and “nucleoside” as defined herein.
- the present invention can make use of conventional detectable labels. Detection can be carried out by any suitable method, including fluorescence spectroscopy or by other optical means.
- the preferred label is a fluorophore, which, after absorption of energy, emits radiation at a defined wavelength.
- Many suitable fluorescent labels are known. For example, Welch et al. ( Chem. Eur. J. 5(3):951-960, 1999) discloses dansyl-functionalised fluorescent moieties that can be used in the present invention. Zhu et al. ( Cytometry 28:206-211, 1997) describes the use of the fluorescent labels Cy3 and Cy5, which can also be used in the present invention. Labels suitable for use are also disclosed in Prober et al.
- fluorescent labels include, but are not limited to, fluorescein, rhodamine (including TMR, texas red and Rox), alexa, bodipy, acridine, coumarin, pyrene, benzanthracene and the cyanins.
- microparticles including quantum dots (Empodocles, et al., Nature 399:126-130, 1999), gold nanoparticles (Reichert et al., Anal. Chem. 72:6025-6029, 2000), microbeads (Lacoste et al., Proc. Natl. Acad. Sci USA 97(17):9461-9466, 2000), and tags detectable by mass spectrometry can all be used.
- the label (or label and linker construct) can be of a size or structure sufficient to act as a block to the incorporation of a further nucleotide onto the nucleotide of the invention. This permits controlled polymerization to be carried out.
- the block can be due to steric hindrance, or can be due to a combination of size, charge and structure.
- nucleotides are also intended to be applicable to nucleosides.
- the invention will also be further described with reference to DNA, although the description will also be applicable to RNA, PNA, and other nucleic acids, unless otherwise indicated.
- the modified nucleotides of the invention use a cleavable linker to attach the label to the nucleotide.
- a cleavable linker ensures that the label can, if required, be removed after detection, avoiding any interfering signal with any labelled nucleotide incorporated subsequently.
- cleavable linker is not meant to imply that the whole linker is required to be removed from the nucleotide base.
- the cleavage site can be located at a position on the linker that ensures that part of the linker remains attached to the nucleotide base after cleavage.
- the linker can be attached at any position on the nucleotide base provided that Watson-Crick base pairing can still be carried out.
- the linker is attached via the 7 position of the purine or the preferred deazapurine analogue, via an 8-modified purine, via an N-6 modified adenosine or an N-2 modified guanine.
- attachment is preferably via the S position on cytidine, thymidine or uracil and the N-4 position on cytosine.
- Suitable nucleotide structures are shown in FIG. 1 .
- X can be H, phosphate, diphosphate or triphosphate.
- R 1 and R 2 can be the same or different, and can be selected from H, OH, or any group which can be transformed into an OH, including, but not limited to, a carbonyl.
- Some suitable functional groups for R 1 and R 2 include the structures shown in FIG. 3 .
- Suitable linkers include, but are not limited to, disulfide linkers (1), acid labile linkers (2, 3, 4 and 5; including dialkoxybenzyl linkers (e.g., 2), Sieber linkers (e.g., 3), indole linkers (e.g., 4), t-butyl Sieber linkers (e.g., 5)), electrophilically cleavable linkers, nucleophilically cleavable linkers, photocleavable linkers, cleavage under reductive conditions, oxidative conditions, cleavage via use of safety-catch linkers, and cleavage by elimination mechanisms.
- disulfide linkers (1)
- acid labile linkers (2, 3, 4 and 5
- Sieber linkers e.g., 3
- indole linkers e.g., 4
- t-butyl Sieber linkers e.g., 5
- electrophilically cleavable linkers nucleophilically cleav
- Electrophilically cleaved linkers are typically cleaved by protons and include cleavages sensitive to acids.
- Suitable linkers include the modified benzylic systems such as trityl, p-alkoxybenzyl esters and p-alkoxybenzyl amides.
- Other suitable linkers include tert-butyloxycarbonyl (Boc) groups and the acetal system (e.g., as is shown in FIG. 3 as O—C(R 4 )(R 5 )—O—R 6 .
- thiophilic metals such as nickel, silver or mercury
- thioacetal or other sulphur-containing protecting groups can also be considered for the preparation of suitable linker molecules.
- Nucleophilic cleavage is also a well recognised method in the preparation of linker molecules.
- Groups such as esters that are labile in water (i.e., can be cleaved simply at basic pH) and groups that are labile to non-aqueous nucleophiles, can be used.
- Fluoride ions can be used to cleave silicon-oxygen bonds in groups such as triisopropyl silane (TIPS) or t-butyldimethyl silane (TBDMS).
- Photocleavable linkers have been used widely in carbohydrate chemistry. It is preferable that the light required to activate cleavage does not affect the other components of the modified nucleotides. For example, if a fluorophore is used as the label, it is preferable if this absorbs light of a different wavelength to that required to cleave the linker molecule.
- Suitable linkers include those based on O-nitrobenyl compounds and nitroveratryl compounds. Linkers based on benzoin chemistry can also be used (Lee et al., J. Org. Chem. 64:3454-3460, 1999).
- linkers There are many linkers known that are susceptible to reductive cleavage. Catalytic hydrogenation using palladium-based catalysts has been used to cleave benzyl and benzyloxycarbonyl groups. Disulphide bond reduction is also known in the art.
- Oxidation-based approaches are well known in the art. These include oxidation of p-alkoxybenzyl groups and the oxidation of sulphur and selenium linkers. The use of aqueous iodine to cleave disulphides and other sulphur or selenium-based linkers is also within the scope of the invention.
- Safety-catch linkers are those that cleave in two steps.
- the first step is the generation of a reactive nucleophilic center followed by a second step involving an intra-molecular cyclization that results in cleavage.
- levulinic ester linkages can be treated with hydrazine or photochemistry to release an active amine, which can then be cyclised to cleave an ester elsewhere in the molecule (Burgess et al., J Org. Chem. 62:5165-5168, 1997).
- Elimination reactions can also be used.
- the base-catalysed elimination of groups such as Fmoc and cyanoethyl, and palladium-catalysed reductive elimination of allylic systems can be used.
- the linker can comprise a spacer unit.
- the spacer distances the nucleotide base from the cleavage site or label.
- the length of the linker is unimportant provided that the label is held a sufficient distance from the nucleotide so as not to interfere with any interaction between the nucleotide and an enzyme.
- the modified nucleotides can also comprise additional groups or modifications to the sugar group.
- a dideoxyribose derivative lacking two oxygens on the ribose ring structure (at the 2′ and 3′ positions), can be prepared and used as a block to further nucleotide incorporation on a growing oligonucleotide strand.
- the ribose ring can also be modified to include a protecting group at the 3′ position or a group that can be transformed or modified to form a 3′ OH group.
- the protecting group is intended to prevent nucleotide incorporation onto a nascent polynucleotide strand, and can be removed under defined conditions to allow polymerisation to occur.
- there is no detectable label attached at the ribose 3′ position This ensures that steric hindrance with the polymerase enzyme is reduced, while still allowing control of incorporation using the protecting group.
- the skilled person will appreciate how to attach a suitable protecting group to the ribose ring to block interactions with the 3′-OH.
- the protecting group can be attached directly at the 3′ position, or can be attached at the 2′ position (the protecting group being of sufficient size or charge to block interactions at the 3′ position).
- the protecting group can be attached at both the 3′ and 2′ positions, and can be cleaved to expose the 3′OH group.
- Suitable protecting groups will be apparent to the skilled person, and can be formed from any suitable protecting group disclosed in Green and Wuts, supra. Some examples of such protecting groups are shown in FIG. 3 .
- the protecting group should be removable (or modifiable) to produce a 3′ OH group.
- the process used to obtain the 3′ OH group can be any suitable chemical or enzymic reaction.
- the labile linker may consist of functionality cleavable under identical conditions to the block. This will make the deprotection process more efficient as only a single treatment will be required to cleave both the label and the block.
- the linker may contain functional groups as described in FIG. 3 , which could be cleaved with the hydroxyl functionality on either the residual nucleoside or the removed label.
- the linker may also consist of entirely different chemical functionality that happens to be labile to the conditions used to cleave the block.
- alkyl covers both straight chain and branched chain alkyl groups. Unless the context indicates otherwise, the term “alkyl” refers to groups having 1 to 8 carbon atoms, and typically from 1 to 6 carbon atoms, for example from 1 to 4 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl butyl, 3-methyl butyl, and n-hexyl and its isomers.
- cycloalkyl groups are those having from 3 to 10 ring atoms, particular examples including those derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane, bicycloheptane and decalin.
- alkenyl groups include, but are not limited to, ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, butenyl, buta-1,4-dienyl, pentenyl, and hexenyl.
- cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl and cyclohexenyl.
- alkoxy refers to C 1-6 alkoxy unless otherwise indicated: —OR, wherein R is a C 1-6 alkyl group.
- C 1-6 alkoxy groups include, but are not limited to, —OMe (methoxy), —OEt (ethoxy), —O(nPr) (n-propoxy), —O(iPr) (isopropoxy), —O(nBu) (n-butoxy), —O(sBu) (sec-butoxy), —O(iBu) (isobutoxy), and —O(tBu) (tert-butoxy).
- amino refers to groups of type NR 1 R 2 , wherein R 1 and R 2 are independently selected from hydrogen, a C 1-6 alkyl group (also referred to as C 1-6 alkylamino or di-C 1-6 alkylamino).
- nucleotide molecules of the present invention are suitable for use in many different methods where the detection of nucleotides is required.
- DNA sequencing methods such as those outlined in U.S. Pat. No. 5,302,509 can be carried out using the nucleotides.
- a method for determining the sequence of a target polynucleotide can be carried out by contacting the target polynucleotide separately with the different nucleotides to form the complement to that of the target polynucleotide, and detecting the incorporation of the nucleotides.
- Such a method makes use of polymerisation, whereby a polymerase enzyme extends the complementary strand by incorporating the correct nucleotide complementary to that on the target.
- the polymerisation reaction also requires a specific primer to initiate polymerisation.
- the incorporation of the labelled nucleotide is carried out by the polymerase enzyme, and the incorporation event is then determined.
- polymerase enzymes include DNA polymerase I, the Klenow fragment, DNA polymerase III, T4 or T7 DNA polymerase, Taq polymerase or vent polymerase.
- a polymerase engineered to have specific properties can also be used.
- the polynucleotides are attached directly onto a planar surface, preferably a planar glass surface. Attachment will preferably be by means of a covalent linkage.
- the arrays that are used are single molecule arrays that comprise polynucleotides in distinct optically resolvable areas, e.g., as disclosed in International App. No. WO 00/06770.
- the sequencing method can be carried out on both single polynucleotide molecule and multi-polynucleotide molecule arrays, i.e., arrays of distinct individual polynucleotide molecules and arrays of distinct regions comprising multiple copies of one individual polynucleotide molecule.
- Single molecule arrays allow each individual polynucleotide to be resolved separately. The use of single molecule arrays is preferred. Sequencing single molecule arrays non-destructively allows a spatially addressable array to be formed.
- the primer sequence may be added as a separate component with respect to the target polynucleotide.
- the primer and the target polynucleotide may each be part of one single stranded molecule, with the primer portion forming an intramolecular duplex with a part of the target, i.e., a hairpin loop structure. This structure may be immobilised to the solid support at any point on the molecule.
- Other conditions necessary for carrying out the polymerase reaction including temperature, pH, buffer compositions etc., will be apparent to those skilled in the art.
- Nucleotides that are not incorporated are then removed, for example, by subjecting the array to a washing step, and detection of the incorporated labels may then be carried out.
- modified nucleotides is not limited to DNA sequencing techniques, and other techniques, including polynucleotide synthesis, DNA hybridisation assays and single nucleotide polymorphism studies, may also be carried out using nucleotides of the invention. Any technique that involves the interaction between a nucleotide and an enzyme may make use of the molecules of the invention.
- the molecule may be used as a substrate for a reverse transcriptase or terminal transferase enzyme.
- Triphosphate (1) was successfully incorporated using Klenow DNA polymerase.
- the reaction was performed in the following conditions: 50 mM Tris.HCl (pH 7.5), 10 mM NaCl, 2 mM DTT, 0.1 mM EDTA, 5 mM MgCl 2 , 2 ⁇ M compound 3, 100 nM DNA template (previously labelled with P32 and T4 polynucleotide kinase) and 10 units of commercial exo-Klenow (Amersham Corp., Arlington Heights, Ill., USA).
- the DNA templates were self-complementary hairpins (5′-TACCgTCgACgTCgACgCTggCg-AgCgTgCTgCggTTTTT(C6-amino)TTACCgCAgCACgCTCgCCAgCg; SEQ ID NO:1).
- the reaction was performed in 100 ⁇ L volume at 37° C. with timepoints taken at 0, 1, 3, 5 and 10 min.
- the reaction products were electrophoresed down a denaturing (8 M urea) 20% polyacrylamide gel and imaged on a typhoon phosphorimager. Complete single base extension was seen in 1 minute indicating efficient polymerase incorporation (disulfide linker gel, FIG. 3 ).
- the reaction mixture was diluted with dichloromethane (100 mL) and the resulting solution was extracted with 1 M aqueous potassium dihydrogen phosphate (50 mL).
- the DCM layer was separated and evaporated under reduced pressure.
- the residue was purified by a short column chromatography. The fractions eluting with 40% methanol in chloroform were collected and evaporated under reduced pressure.
- the residue was then dissolved in dry DMF (1 mL) and N-(2-mercaptoethyl)aminomethyl polystyrene (200 mg, 400 ⁇ mop and DBU (12 ⁇ l, 80 ⁇ mol). After 10 minutes at room temperature, the resins were filtered off and rinsed with dry DMF (1 mL).
- TMR-sieber linker free acid (4.34 mg, 5 ⁇ mop was stirred with disuccinimidyl carbonate (1.74 mg, 7.5 ⁇ mol) and N,N-dimethyl aminopyridine (0.92 mg, 7.5 ⁇ mol) in DMF (1 mL) at room temperature. After 10 minutes, all the reaction mixture was added to tetra-(tri-butylammonium) salt of 5-(3-aminopropynyl)-2′-deoxyuridine-5′-triphosphate (10 ⁇ mol). The reaction was stirred at room temperature for 4 hrs and stored in the fridge overnight. The reaction mixture was then diluted with chilled water (10 mL) and all the resulting solution was applied onto a short column of DEAE A-25.
- Triphosphate (3) was successfully incorporated using Klenow DNA polymerase.
- the reaction was performed in the following conditions: 50 mM Tris.HCl (pH 7.5), 10 mM NaCl, 2 mM DTT, 0.1 mM EDTA, 5 mM MgCl 2 , 2 ⁇ M compound 3, 100 nM DNA template (previously labelled with P32 and T4 polynucleotide kinase) and 10 units of commercial exo-Klenow (Amersham Corp. Arlington Heights, Ill., USA).
- the DNA templates were self-complementary hairpins (5′-TACCgTCgACgTCgACgCTggCg-AgCgTgCTgCggTTTTT(C6-amino)TTACCgCAgCACgCTCgCCAgCg; SEQ ID NO:1).
- the reaction was performed in 100 ⁇ L volume at 37° C. with timepoints taken at 0, 1, 3, 5 and 10 min.
- the reaction products were electrophoresed down a denaturing (8 M urea) 20% polyacrylamide gel and imaged on a typhoon phosphorimager. Complete single base extension was seen in 1 minute indicating efficient polymerase incorporation (indole linker gel, FIG. 5 ).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Nucleosides and nucleotides are disclosed that are linked to detectable labels via a cleavable linker group.
Description
- This application is a division of U.S. patent application Ser. No. 15/354,511, filed Nov. 17, 2016; which is a continuation of U.S. patent application Ser. No. 15/202,456, filed Jul. 5, 2016, now U.S. Pat. No. 10,480,025; which is a continuation of U.S. patent application Ser. No. 14/857,671, filed Sep. 17, 2015, now U.S. Pat. No. 9,410,200; which is a continuation of U.S. patent application Ser. No. 13/791,597, filed Mar. 8, 2013, now U.S. Pat. No. 9,388,463; which is a continuation of U.S. patent application Ser. No. 13/432,989, filed Mar. 28, 2012, now U.S. Pat. No. 8,394,586; which is a continuation of U.S. patent application Ser. No. 12/804,296, filed Jul. 19, 2010, now U.S. Pat. No. 8,148,064; which is a continuation of U.S. patent application Ser. No. 12/460,741, filed Jul. 23, 2009, now U.S. Pat. No. 7,785,796; which is a division of U.S. patent application Ser. No. 11/301,578, filed Dec. 13, 2005, now U.S. Pat. No. 7,566,537; which is a division of U.S. patent application Ser. No. 10/227,131, filed Aug. 23, 2002, now U.S. Pat. No. 7,057,026; which claims benefit of United Kingdom Application No. GB0129012.1, filed Dec. 4, 2001; the contents of each is incorporated by reference in its entirety.
- The present application includes a sequence listing in Electronic format. The Sequence Listing is provided as a file entitled “ILLINC371D3 sequence listing.txt”, which is approximately 824 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
- This invention relates to labelled nucleotides. In particular, this invention discloses nucleotides having a removable label and their use in polynucleotide sequencing methods.
- Advances in the study of molecules have been led, in part, by improvement in technologies used to characterise the molecules or their biological reactions. In particular, the study of the nucleic acids DNA and RNA has benefited from developing technologies used for sequence analysis and the study of hybridisation events.
- An example of the technologies that have improved the study of nucleic acids, is the development of fabricated arrays of immobilised nucleic acids. These arrays consist typically of a high-density matrix of polynucleotides immobilised onto a solid support material. See, e.g., Fodor et al., Trends Biotech. 12:19-26, 1994, which describes ways of assembling the nucleic acids using a chemically sensitized glass surface protected by a mask, but exposed at defined areas to allow attachment of suitably modified nucleotide phosphoramidites. Fabricated arrays can also be manufactured by the technique of “spotting” known polynucleotides onto a solid support at predetermined positions (e.g., Stimpson et al., Proc. Natl. Acad. Sci. USA 92:6379-6383, 1995).
- A further development in array technology is the attachment of the polynucleotides to the solid support material to form single molecule arrays. Arrays of this type are disclosed in International Patent App. WO 00/06770. The advantage of these arrays is that reactions can be monitored at the single molecule level and information on large numbers of single molecules can be collated from a single reaction.
- For DNA arrays to be useful, the sequences of the molecules must be determined. U.S. Pat. No. 5,302,509 discloses a method to sequence polynucleotides immobilised on a solid support. The method relies on the incorporation of 3′-blocked bases A, G, C and T having a different fluorescent label to the immobilised polynucleotide, in the presence of DNA polymerase. The polymerase incorporates a base complementary to the target polynucleotide, but is prevented from further addition by the 3′-blocking group. The label of the incorporated base can then be determined and the blocking group removed by chemical cleavage to allow further polymerisation to occur.
- Welch et al. (Chem. Eur. J. 5(3):951-960, 1999) describes the synthesis of nucleotide triphosphates modified with a 3′-O-blocking group that is photolabile and fluorescent. The modified nucleotides are intended for use in DNA sequencing experiments. However, these nucleotides proved to be difficult to incorporate onto an existing polynucleotide, due to an inability to fit into the polymerase enzyme active site.
- Zhu et al. (Cytometry 28:206-211, 1997) also discloses the use of fluorescent labels attached to a nucleotide via the base group. The labelled nucleotides are intended for use in fluorescence in situ hybridisation (FISH) experiments, where a series of incorporated labelled nucleotides is required to produce a fluorescent “bar code”.
- In the present invention, a nucleoside or nucleotide molecule is linked to a detectable label via a cleavable linker group attached to the base, rendering the molecule useful in techniques using Labelled nucleosides or nucleotides, e.g., sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridization assays, single nucleotide polymorphism studies, and other techniques using enzymes such as polymerases, reverse transcriptases, terminal transferases, or other DNA modifying enzymes. The invention is especially useful in techniques that use Labelled dNTPs, such as nick translation, random primer labeling, end-labeling (e.g., with terminal deoxynucleotidyltransferase), reverse transcription, or nucleic acid amplification. The molecules of the present invention are in contrast to the prior art, where the label is attached to the ribose or deoxyribose sugar, or where the label is attached via a non-cleavable linker.
- According to a first aspect of the invention, a nucleotide or nucleoside molecule, or an analog thereof, has a base that is linked to a detectable label via a cleavable linker.
- The invention features a nucleotide or nucleoside molecule, having a base that is linked to a detectable label via a cleavable linker. The base can be a purine, or a pyrimidine. The base can be a deazapurine. The molecule can have a ribose or deoxyribose sugar moiety. The ribose or deoxyribose sugar can include a protecting group attached via the 2′ or 3′ oxygen atom. The protecting group can be removed to expose a 3′-OH. The molecule can be a deoxyribonucleotide triphosphate. The detectable label can be a fluorophore. The linker can be an acid labile linker, a photolabile linker, or can contain a disulphide linkage.
- The invention also features a method of labeling a nucleic acid molecule, where the method includes incorporating into the nucleic acid molecule a nucleotide or nucleoside molecule, where the nucleotide or nucleoside molecule has a base that is linked to a detectable label via a cleavable linker. The incorporating step can be accomplished via a terminal transferase, a polymerase or a reverse transcriptase. The base can be a purine, or a pyrimidine. The base can be a deazapurine. The nucleotide or nucleoside molecule can have a ribose or deoxyribose sugar moiety. The ribose or deoxyribose sugar can include a protecting group attached via the 2′ or 3′ oxygen atom. The protecting group can be removed to expose a 3′-OH group. The molecule can be a deoxyribonucleotide triphosphate. The detectable label can be a fluorophore. The linker can be an acid labile linker, a photolabile linker, or can contain a disulphide linkage. The detectable label and/or the cleavable linker can be of a size sufficient to prevent the incorporation of a second nucleotide or nucleoside into the nucleic acid molecule.
- In another aspect, the invention features a method for determining the sequence of a target single-stranded polynucleotide, where the method includes monitoring the sequential incorporation of complementary nucleotides, where the nucleotides each have a base that is linked to a detectable label via a cleavable linker, and where the identity of each nucleotide incorporated is determined by detection of the label linked to the base, and subsequent removal of the label.
- The invention also features a method for determining the sequence of a target single-stranded polynucleotide, where the method includes: (a) providing nucleotides, where the nucleotides have a base that is linked to a detectable label via a cleavable linker, and where the detectable label linked to each type of nucleotide can be distinguished upon detection from the detectable label used for other types of nucleotides; (b) incorporating a nucleotide into the complement of the target single stranded polynucleotide; (c) detecting the label of the nucleotide of (b), thereby determining the type of nucleotide incorporated; (d) removing the label of the nucleotide of (b); and (e) optionally repeating steps (b)-(d) one or more times; thereby determining the sequence of a target single-stranded polynucleotide.
- In the methods described herein, each of the nucleotides can be brought into contact with thew target sequentially, with removal of non-incorporated nucleotides prior to addition of the next nucleotide, where detection and removal of the label is carried out either after addition of each nucleotide, or after addition of all four nucleotides.
- In the methods, all of the nucleotides can be brought into contact with the target simultaneously, i.e., a composition comprising all of the different nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label(s).
- The methods can comprise a first step and a second step, where in the first step, a first composition comprising two of the four nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where in the second step, a second composition comprising the two nucleotides not included in the first composition is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where the first steps and the second step can be optionally repeated one or more times.
- The methods described herein can also comprise a first step and a second step, where in the first step, a composition comprising one of the four nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where in the second step, a second composition comprising the three nucleotides not included in the first composition is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where the first steps and the second step can be optionally repeated one or more times.
- The methods described herein can also comprise a first step and a second step, where in the first step, a first composition comprising three of the four nucleotides is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where in the second step, a composition comprising the nucleotide not included in the first composition is brought into contact with the target, and non-incorporated nucleotides are removed prior to detection and subsequent to removal of the label, and where the first steps and the second step can be optionally repeated one or more times.
- In a further aspect, the invention features a kit, where the kit includes: (a) individual the nucleotides, where each nucleotide has a base that is linked to a detectable label via a cleavable linker, and where the detectable label linked to each nucleotide can be distinguished upon detection from the detectable label used for other three nucleotides; and (b) packaging materials therefor. The kit can further include an enzyme and buffers appropriate for the action of the enzyme.
- The nucleotides/nucleosides are suitable for use in many different DNA-based methodologies, including DNA synthesis and DNA sequencing protocols.
- According to another aspect of the invention, a method for determining the sequence of a target polynucleotide comprises monitoring the sequential incorporation of complementary nucleotides, wherein the nucleotides comprise a detectable label linked to the base portion of the nucleotide via a cleavable linker, incorporation is detected by monitoring the label, and the label is removed to permit further nucleotide incorporation to occur.
-
FIG. 1 shows exemplary nucleotide structures useful in the invention. For each structure, X can be H, phosphate, diphosphate or triphosphate. R1 and R2 can be the same or different, and can be selected from H, OH, or any group which can be transformed into an OH, including, but not limited to, a carbonyl. Some suitable functional groups for R1 and R2 include the structures shown inFIG. 3 . -
FIG. 2 shows structures of linkers useful in the invention, including (1) disulfide linkers and acid labile linkers, (2) dialkoxybenzyl linkers, (3) Sieber linkers, (4) indole linkers and (5) t-butyl Sieber linkers. -
FIG. 3 shows some functional molecules useful in the invention, including some cleavable linkers and some suitable hydroxyl protecting groups. In these structures, R1 and R2 may be the same of different, and can be H, OH, or any group which can be transformed into an OH group, including a carbonyl. R3 represents one or more substituents independently selected from alkyl, alkoxyl, amino or halogen groups. Alternatively, cleavable linkers may be constructed from any labile functionality used on the 3′-block. R4 and R5 can be H or alkyl, and R6 can be alkyl, cycloalkyl, alkenyl, cycloalkenyl or benzyl. X can be H, phosphate, diphosphate or triphosphate. -
FIG. 4 shows a denaturing gel showing the incorporation of the triphosphate of Example 1 using Klenow polymerase. -
FIG. 5 shows a denaturing gel showing the incorporation of the triphosphate of Example 3 using Klenow polymerase. -
FIG. 6 shows a denaturing gel showing the incorporation of the triphosphate of Example 4 using Klenow polymerase. - The present invention relates to nucleotides and nucleosides that are modified by attachment of a label via a cleavable linker, thereby rendering the molecule useful in techniques where the labelled molecule is to interact with an enzyme, such as sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridization assays, single nucleotide polymorphism studies, techniques using enzymes such as polymerase, reverse transcriptase, terminal transferase, techniques that use Labelled dNTPs (e.g., nick translation, random primer labeling, end-labeling (e.g., with terminal deoxynucleotidyltransferase), reverse transcription, or nucleic acid amplification).
- As is known in the art, a “nucleotide” consists of a nitrogenous base, a sugar, and one or more phosphate groups. In RNA, the sugar is a ribose, and in DNA is a deoxyribose, i.e., a sugar lacking a hydroxyl group that is present in ribose. The nitrogenous base is a derivative of purine or pyrimidine. The purines are adenosine (A) and guanidine (G), and the pyrimidines are cytidine (C) and thymidine (T) (or in the context of RNA, uracil (U)). The C-1 atom of deoxyribose is bonded to N-1 of a pyrimidine or N-9 of a purine. A nucleotide is also a phosphate ester of a nucleoside, with esterification occurring on the hydroxyl group attached to C-5 of the sugar. Nucleotides are usually mono, di- or triphosphates.
- A “nucleoside” is structurally similar to a nucleotide, but are missing the phosphate moieties. An example of a nucleoside analog would be one in which the label is linked to the base and there is no phosphate group attached to the sugar molecule.
- Although the base is usually referred to as a purine or pyrimidine, the skilled person will appreciate that derivatives and analogs are available which do not alter the capability of the nucleotide or nucleoside to undergo Watson-Crick base pairing. “Derivative” or “analog” means a compound or molecule whose core structure is the same as, or closely resembles that of, a parent compound, but which has a chemical or physical modification, such as a different or additional side groups, which allows the derivative nucleotide or nucleoside to be linked to another molecule. For example, the base can be a deazapurine. The derivatives should be capable of undergoing Watson-Crick pairing. “Derivative” and “analog” also mean a synthetic nucleotide or nucleoside derivative having modified base moieties and/or modified sugar moieties. Such derivatives and analogs are discussed in, e.g., Scheit, Nucleotide Analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90:543-584, 1990. Nucleotide analogs can also comprise modified phosphodiester linkages, including phosphorothioate, phosphorodithioate, alkylphosphonate, phosphoranilidate and phosphoramidate linkages. The analogs should be capable of undergoing Watson-Crick base pairing. “Derivative” and “analog”, as used herein, may be used interchangeably, and are encompassed by the terms “nucleotide” and “nucleoside” as defined herein.
- The present invention can make use of conventional detectable labels. Detection can be carried out by any suitable method, including fluorescence spectroscopy or by other optical means. The preferred label is a fluorophore, which, after absorption of energy, emits radiation at a defined wavelength. Many suitable fluorescent labels are known. For example, Welch et al. (Chem. Eur. J. 5(3):951-960, 1999) discloses dansyl-functionalised fluorescent moieties that can be used in the present invention. Zhu et al. (Cytometry 28:206-211, 1997) describes the use of the fluorescent labels Cy3 and Cy5, which can also be used in the present invention. Labels suitable for use are also disclosed in Prober et al. (Science 238:336-341, 1987); Connell et al. (BioTechniques 5(4):342-384, 1987), Ansorge et al. (Nucl. Acids Res. 15(11):4593-4602, 1987) and Smith et al. (Nature 321:674, 1986). Other commercially available fluorescent labels include, but are not limited to, fluorescein, rhodamine (including TMR, texas red and Rox), alexa, bodipy, acridine, coumarin, pyrene, benzanthracene and the cyanins.
- Multiple labels can also be used in the invention. For example, bi-fluorophore FRET cassettes (Tet. Letts. 46:8867-8871, 2000) are well known in the art and can be utilised in the present invention. Multi-fluor dendrimeric systems (J. Amer. Chem. Soc. 123:8101-8108, 2001) can also be used.
- Although fluorescent labels are preferred, other forms of detectable labels will be apparent as useful to those of ordinary skill. For example, microparticles, including quantum dots (Empodocles, et al., Nature 399:126-130, 1999), gold nanoparticles (Reichert et al., Anal. Chem. 72:6025-6029, 2000), microbeads (Lacoste et al., Proc. Natl. Acad. Sci USA 97(17):9461-9466, 2000), and tags detectable by mass spectrometry can all be used.
- Multi-component labels can also be used in the invention. A multi-component label is one which is dependent on the interaction with a further compound for detection. The most common multi-component label used in biology is the biotin-streptavidin system. Biotin is used as the label attached to the nucleotide base. Streptavidin is then added separately to enable detection to occur. Other multi-component systems are available. For example, dinitrophenol has a commercially available fluorescent antibody that can be used for detection.
- The label (or label and linker construct) can be of a size or structure sufficient to act as a block to the incorporation of a further nucleotide onto the nucleotide of the invention. This permits controlled polymerization to be carried out. The block can be due to steric hindrance, or can be due to a combination of size, charge and structure.
- The invention will be further described with reference to nucleotides. However, unless indicated otherwise, the reference to nucleotides is also intended to be applicable to nucleosides. The invention will also be further described with reference to DNA, although the description will also be applicable to RNA, PNA, and other nucleic acids, unless otherwise indicated.
- The modified nucleotides of the invention use a cleavable linker to attach the label to the nucleotide. The use of a cleavable linker ensures that the label can, if required, be removed after detection, avoiding any interfering signal with any labelled nucleotide incorporated subsequently.
- Cleavable linkers are known in the art, and conventional chemistry can be applied to attach a linker to a nucleotide base and a label. The linker can be cleaved by any suitable method, including exposure to acids, bases, nucleophiles, electrophiles, radicals, metals, reducing or oxidising agents, light, temperature, enzymes etc. Suitable linkers can be adapted from standard chemical blocking groups, as disclosed in Greene & Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons. Further suitable cleavable linkers used in solid-phase synthesis are disclosed in Guillier et al. (Chem. Rev. 100:2092-2157, 2000).
- The use of the term “cleavable linker” is not meant to imply that the whole linker is required to be removed from the nucleotide base. The cleavage site can be located at a position on the linker that ensures that part of the linker remains attached to the nucleotide base after cleavage.
- The linker can be attached at any position on the nucleotide base provided that Watson-Crick base pairing can still be carried out. In the context of purine bases, it is preferred if the linker is attached via the 7 position of the purine or the preferred deazapurine analogue, via an 8-modified purine, via an N-6 modified adenosine or an N-2 modified guanine. For pyrimidines, attachment is preferably via the S position on cytidine, thymidine or uracil and the N-4 position on cytosine. Suitable nucleotide structures are shown in
FIG. 1 . For each structure inFIG. 1 , X can be H, phosphate, diphosphate or triphosphate. R1 and R2 can be the same or different, and can be selected from H, OH, or any group which can be transformed into an OH, including, but not limited to, a carbonyl. Some suitable functional groups for R1 and R2 include the structures shown inFIG. 3 . - Suitable linkers are shown in
FIG. 2 and include, but are not limited to, disulfide linkers (1), acid labile linkers (2, 3, 4 and 5; including dialkoxybenzyl linkers (e.g., 2), Sieber linkers (e.g., 3), indole linkers (e.g., 4), t-butyl Sieber linkers (e.g., 5)), electrophilically cleavable linkers, nucleophilically cleavable linkers, photocleavable linkers, cleavage under reductive conditions, oxidative conditions, cleavage via use of safety-catch linkers, and cleavage by elimination mechanisms. - Electrophilically cleaved linkers are typically cleaved by protons and include cleavages sensitive to acids. Suitable linkers include the modified benzylic systems such as trityl, p-alkoxybenzyl esters and p-alkoxybenzyl amides. Other suitable linkers include tert-butyloxycarbonyl (Boc) groups and the acetal system (e.g., as is shown in
FIG. 3 as O—C(R4)(R5)—O—R6. - The use of thiophilic metals, such as nickel, silver or mercury, in the cleavage of thioacetal or other sulphur-containing protecting groups can also be considered for the preparation of suitable linker molecules.
- Nucleophilic cleavage is also a well recognised method in the preparation of linker molecules. Groups such as esters that are labile in water (i.e., can be cleaved simply at basic pH) and groups that are labile to non-aqueous nucleophiles, can be used. Fluoride ions can be used to cleave silicon-oxygen bonds in groups such as triisopropyl silane (TIPS) or t-butyldimethyl silane (TBDMS).
- Photocleavable linkers have been used widely in carbohydrate chemistry. It is preferable that the light required to activate cleavage does not affect the other components of the modified nucleotides. For example, if a fluorophore is used as the label, it is preferable if this absorbs light of a different wavelength to that required to cleave the linker molecule. Suitable linkers include those based on O-nitrobenyl compounds and nitroveratryl compounds. Linkers based on benzoin chemistry can also be used (Lee et al., J. Org. Chem. 64:3454-3460, 1999).
- There are many linkers known that are susceptible to reductive cleavage. Catalytic hydrogenation using palladium-based catalysts has been used to cleave benzyl and benzyloxycarbonyl groups. Disulphide bond reduction is also known in the art.
- Oxidation-based approaches are well known in the art. These include oxidation of p-alkoxybenzyl groups and the oxidation of sulphur and selenium linkers. The use of aqueous iodine to cleave disulphides and other sulphur or selenium-based linkers is also within the scope of the invention.
- Safety-catch linkers are those that cleave in two steps. In a preferred system the first step is the generation of a reactive nucleophilic center followed by a second step involving an intra-molecular cyclization that results in cleavage. For example, levulinic ester linkages can be treated with hydrazine or photochemistry to release an active amine, which can then be cyclised to cleave an ester elsewhere in the molecule (Burgess et al., J Org. Chem. 62:5165-5168, 1997).
- Elimination reactions can also be used. For example, the base-catalysed elimination of groups such as Fmoc and cyanoethyl, and palladium-catalysed reductive elimination of allylic systems, can be used.
- As well as the cleavage site, the linker can comprise a spacer unit. The spacer distances the nucleotide base from the cleavage site or label. The length of the linker is unimportant provided that the label is held a sufficient distance from the nucleotide so as not to interfere with any interaction between the nucleotide and an enzyme.
- The modified nucleotides can also comprise additional groups or modifications to the sugar group. For example, a dideoxyribose derivative, lacking two oxygens on the ribose ring structure (at the 2′ and 3′ positions), can be prepared and used as a block to further nucleotide incorporation on a growing oligonucleotide strand. The ribose ring can also be modified to include a protecting group at the 3′ position or a group that can be transformed or modified to form a 3′ OH group. The protecting group is intended to prevent nucleotide incorporation onto a nascent polynucleotide strand, and can be removed under defined conditions to allow polymerisation to occur. In contrast to the prior art, there is no detectable label attached at the
ribose 3′ position. This ensures that steric hindrance with the polymerase enzyme is reduced, while still allowing control of incorporation using the protecting group. - The skilled person will appreciate how to attach a suitable protecting group to the ribose ring to block interactions with the 3′-OH. The protecting group can be attached directly at the 3′ position, or can be attached at the 2′ position (the protecting group being of sufficient size or charge to block interactions at the 3′ position). Alternatively, the protecting group can be attached at both the 3′ and 2′ positions, and can be cleaved to expose the 3′OH group.
- Suitable protecting groups will be apparent to the skilled person, and can be formed from any suitable protecting group disclosed in Green and Wuts, supra. Some examples of such protecting groups are shown in
FIG. 3 . The protecting group should be removable (or modifiable) to produce a 3′ OH group. The process used to obtain the 3′ OH group can be any suitable chemical or enzymic reaction. - The labile linker may consist of functionality cleavable under identical conditions to the block. This will make the deprotection process more efficient as only a single treatment will be required to cleave both the label and the block. Thus the linker may contain functional groups as described in
FIG. 3 , which could be cleaved with the hydroxyl functionality on either the residual nucleoside or the removed label. The linker may also consist of entirely different chemical functionality that happens to be labile to the conditions used to cleave the block. - The term “alkyl” covers both straight chain and branched chain alkyl groups. Unless the context indicates otherwise, the term “alkyl” refers to groups having 1 to 8 carbon atoms, and typically from 1 to 6 carbon atoms, for example from 1 to 4 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl butyl, 3-methyl butyl, and n-hexyl and its isomers.
- Examples of cycloalkyl groups are those having from 3 to 10 ring atoms, particular examples including those derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane, bicycloheptane and decalin.
- Examples of alkenyl groups include, but are not limited to, ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, butenyl, buta-1,4-dienyl, pentenyl, and hexenyl.
- Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl and cyclohexenyl.
- The term alkoxy refers to C1-6 alkoxy unless otherwise indicated: —OR, wherein R is a C1-6alkyl group. Examples of C1-6 alkoxy groups include, but are not limited to, —OMe (methoxy), —OEt (ethoxy), —O(nPr) (n-propoxy), —O(iPr) (isopropoxy), —O(nBu) (n-butoxy), —O(sBu) (sec-butoxy), —O(iBu) (isobutoxy), and —O(tBu) (tert-butoxy).
- The term amino refers to groups of type NR1R2, wherein R1 and R2 are independently selected from hydrogen, a C1-6 alkyl group (also referred to as C1-6 alkylamino or di-C1-6 alkylamino).
- The term “halogen” as used herein includes fluorine, chlorine, bromine and iodine.
- The nucleotide molecules of the present invention are suitable for use in many different methods where the detection of nucleotides is required.
- DNA sequencing methods, such as those outlined in U.S. Pat. No. 5,302,509 can be carried out using the nucleotides.
- A method for determining the sequence of a target polynucleotide can be carried out by contacting the target polynucleotide separately with the different nucleotides to form the complement to that of the target polynucleotide, and detecting the incorporation of the nucleotides. Such a method makes use of polymerisation, whereby a polymerase enzyme extends the complementary strand by incorporating the correct nucleotide complementary to that on the target. The polymerisation reaction also requires a specific primer to initiate polymerisation.
- For each cycle, the incorporation of the labelled nucleotide is carried out by the polymerase enzyme, and the incorporation event is then determined. Many different polymerase enzymes exist, and it will be evident to the person of ordinary skill which is most appropriate to use. Preferred enzymes include DNA polymerase I, the Klenow fragment, DNA polymerase III, T4 or T7 DNA polymerase, Taq polymerase or vent polymerase. A polymerase engineered to have specific properties can also be used.
- The sequencing methods are preferably carried out with the target polynucleotide arrayed on a solid support. Multiple target polynucleotides can be immobilised on the solid support through linker molecules, or can be attached to particles, e.g., microspheres, which can also be attached to a solid support material.
- The polynucleotides can be attached to the solid support by a number of means, including the use of biotin-avidin interactions. Methods for immobilizing polynucleotides on a solid support are well known in the art, and include lithographic techniques and “spotting” individual polynucleotides in defined positions on a solid support. Suitable solid supports are known in the art, and include glass slides and beads, ceramic and silicon surfaces and plastic materials. The support is usually a flat surface although microscopic beads (microspheres) can also be used and can in turn be attached to another solid support by known means. The microspheres can be of any suitable size, typically in the range of from 10 nm to 100 nm in diameter. In a preferred embodiment, the polynucleotides are attached directly onto a planar surface, preferably a planar glass surface. Attachment will preferably be by means of a covalent linkage. Preferably, the arrays that are used are single molecule arrays that comprise polynucleotides in distinct optically resolvable areas, e.g., as disclosed in International App. No. WO 00/06770.
- The sequencing method can be carried out on both single polynucleotide molecule and multi-polynucleotide molecule arrays, i.e., arrays of distinct individual polynucleotide molecules and arrays of distinct regions comprising multiple copies of one individual polynucleotide molecule. Single molecule arrays allow each individual polynucleotide to be resolved separately. The use of single molecule arrays is preferred. Sequencing single molecule arrays non-destructively allows a spatially addressable array to be formed.
- The method makes use of the polymerisation reaction to generate the complementary sequence of the target. The conditions necessary for polymerisation to occur will be apparent to the skilled person.
- To carry out the polymerase reaction it will usually be necessary to first anneal a primer sequence to the target polynucleotide, the primer sequence being recognised by the polymerase enzyme and acting as an initiation site for the subsequent extension of the complementary strand. The primer sequence may be added as a separate component with respect to the target polynucleotide. Alternatively, the primer and the target polynucleotide may each be part of one single stranded molecule, with the primer portion forming an intramolecular duplex with a part of the target, i.e., a hairpin loop structure. This structure may be immobilised to the solid support at any point on the molecule. Other conditions necessary for carrying out the polymerase reaction, including temperature, pH, buffer compositions etc., will be apparent to those skilled in the art.
- The modified nucleotides of the invention are then brought into contact with the target polynucleotide, to allow polymerisation to occur. The nucleotides may be added sequentially, i.e., separate addition of each nucleotide type (A, T, G or C), or added together. If they are added together, it is preferable for each nucleotide type to be labelled with a different label.
- This polymerisation step is allowed to proceed for a time sufficient to allow incorporation of a nucleotide.
- Nucleotides that are not incorporated are then removed, for example, by subjecting the array to a washing step, and detection of the incorporated labels may then be carried out.
- Detection may be by conventional means, for example if the label is a fluorescent moiety, detection of an incorporated base may be carried out by using a confocal scanning microscope to scan the surface of the array with a laser, to image a fluorophore bound directly to the incorporated base. Alternatively, a sensitive 2-D detector, such as a charge-coupled detector (CCD), can be used to visualise the individual signals generated. However, other techniques such as scanning near-field optical microscopy (SNOM) are available and may be used when imaging dense arrays. For example, using SNOM, individual polynucleotides may be distinguished when separated by a distance of less than 100 nm, e.g., 10 nm to 10 μm. For a description of scanning near-field optical microscopy, see Moyer et al., Laser Focus World 29:10, 1993. Suitable apparatus used for imaging polynucleotide arrays are known and the technical set-up will be apparent to the skilled person.
- After detection, the label may be removed using suitable conditions that cleave the linker.
- The use of the modified nucleotides is not limited to DNA sequencing techniques, and other techniques, including polynucleotide synthesis, DNA hybridisation assays and single nucleotide polymorphism studies, may also be carried out using nucleotides of the invention. Any technique that involves the interaction between a nucleotide and an enzyme may make use of the molecules of the invention. For example, the molecule may be used as a substrate for a reverse transcriptase or terminal transferase enzyme.
- Suitable structures are described in the following Examples and are shown in the accompanying drawings.
-
- tButyl-N-(2-mercaptoethyl) carbamate (3 mmol, 0.5 mL) was added dropwise to a solution of 1.32 g (6.0 mmol) aldrithiol in 15 mL MeOH. After 1.5 h the reaction had gone to completion and the solvent was evaporated. The crude product was purified by chromatography on silica with ethyl acetate:petroleum ether (1:4). Product 1a was obtained as a slightly yellow oil (0.76 g, 2.67 mmol, 89%). 1H NMR (500 Mhz, D6-DMSO): δ=1.38 (s, 9H, tBu), 2.88 (t, J=6.6 Hz, 2H, SCH2) 3.20 (q, J=6.6 Hz, 2H, CH2 NH), 7.02 (bs, 1H, NH), 7.24 (ddd, J=7.3 Hz, J=4.9 Hz, J=1.0 Hz, 1H, H-5), 7.77 (dt, J=8.1 Hz, J=1.0 Hz, 1H, H-3), 7.82 (ddd, J=8.1 Hz, J=7.4 Hz, J=1.8 Hz, 1H, H-4), 8.46 (ddd, J=4.9 Hz, J=1.8 Hz, J=1.0 Hz, 1H, H-6).
- To deprotect the amine of 1a, 17 mg of 1a (60 μmol) was dissolved in a mixture of 0.5 mL DCM and 0.5 mL trifluoracetic acid. This mixture was stirred for 2.5 h at rt and then the solvents were removed under reduced pressure. The residue was three times redissolved in 2 mL DCM and evaporated to dryness. The deprotected product was dried under high vacuum for 3 h and then dissolved in 1 mL dry DMF. It was assumed that the deprotection had gone to completion.
- To a solution of 15 mg 5-carboxy tetra methyl rhodamine (35 μmop in 2 mL DMF were added 8.0 mg N-hydroxy succinimide (70 μmol) and 7.8 mg DCC (38 μmol). The mixture was stirred for 6 h in the dark. Then 22 μl DIPEA (126 μmol) and the solution of deprotected 1a in 1 mL DMF were added. After stirring the reaction mixture overnight in the dark, the solvent was removed under reduced pressure. The residue was dissolved in DCM and washed with saturated NaCl solution. After drying over MgSO4 the crude mixture was purified on silica with CHCl3:MeOH (3:1) as solvent. 1b was isolated as a dark red solid in 90% yield (19.2 mg, 31.4 μmop. 1H NMR (500 MHz, D6-DMSO): δ=3.09 (t, J=6.7 Hz, 2H, SCH2), 3.63 (q, J=6.2 Hz, 2H, CH2 NH), 6.48-6.53 (m, 6H, H-Anthracene), 7.23-7.26 [m, 1H, H-5 (pyridine)], 7.32 (d, J=7.9 Hz, 1 Hz, H-3), 7.81-7.82 [m, 2H, H-3+H-4 (pyridine)], 8.21 (d, J=7.9 Hz, 1H, H-4), 8.43 (s, 1H, H-6), 8.47 [dt, J=4.7 Hz, J=1.3 Hz, 1H, H-6 (pyridine)], 9.03 (t, J=5.2 Hz, 1H, NH).
- Mercaptopropionic acid (20.6 μmol, 1.8 μl) was added to a solution of 19.6 mg 1b (32.7 μmol) in 2 mL MeOH. The mixture was stirred for 2.5 h in the dark. The solvent was removed under reduced pressure. The crude product was purified by chromatography on silica with CHCl3:MeOH:AcOH 15:1:0.5 as the solvent mixture. 15.5 mg (26 μmol, 80%) dark red crystals 1c could be isolated. 1H NMR (500 MHz, D2O): δ=2.53 (t, J=7.0 Hz, 2H, CH2 COOH), 2.88 (t, J=7.0 Hz, 2H, CH2 CH2COOH), 2.96-2.99 (m, 2H, CH2 CH2NH), 3.73 (t, J=6.3 Hz, 2H, CH2 NH), 6.53 (d, J=2.4 Hz, 2H, H-Anthracene), 6.81 (dd, J=9.5 Hz, J=4.5 Hz, 2H, H-Anthracene), 7.12 (d, J=9.5 Hz, 2H, H-Anthracene), 7.48 (d, J=7.9 Hz, 1H, H-3), 7.95 (dd, J=8.1 Hz, J=1.9 Hz, 1H, H-2) 8.13 (d, J=1.9 Hz, 1H, H-1). +ve electro spray (C30H31N3O6S2): expected 593.17; found 594.3 [M+H], 616.2 [M+Na].
- To a solution of 25.8 mg 1c (43.4 μmol) in 3 mL DMF (dry) were added 9.9 mg N-hydroxy succinimide (86.8 μmol) and 9.7 mg DCC (47.1 μmol). The mixture was stirred in the dark for 5 h at room temperature and then put in the fridge overnight. The mixture was filtered through a plug of cotton wool in a new flask and to this was added a solution of 865 μl propargylamino dUTP (14.7 μmol, 17 μmol in 1 mL H2O) and 3 mL sodium borate buffer (0.1 M solution, pH 9). The mixture was stirred overnight. After removal of solvents the residue was dissolved in as little water as possible and purified by HPLC. A Zorbax C18 column was used with 0.1 M triethyl ammonium bicarbonate (TEAB) and acetonitrile as buffers. 31P NMR (400 MHz, D2O): δ=−4.73 (d), −9.93 (d), 19.03 (t). −ve electro spray (C42H47N6O19P3S2 assuming 4H+ counter ions): expected 1096.16; found 1092.9. UV in Water: λ(max)=555 nm A(555)=0.885 (c=0.036 μmol).
- Triphosphate (1) was successfully incorporated using Klenow DNA polymerase. The reaction was performed in the following conditions: 50 mM Tris.HCl (pH 7.5), 10 mM NaCl, 2 mM DTT, 0.1 mM EDTA, 5 mM MgCl2, 2
μM compound 3, 100 nM DNA template (previously labelled with P32 and T4 polynucleotide kinase) and 10 units of commercial exo-Klenow (Amersham Corp., Arlington Heights, Ill., USA). The DNA templates were self-complementary hairpins (5′-TACCgTCgACgTCgACgCTggCg-AgCgTgCTgCggTTTTT(C6-amino)TTACCgCAgCACgCTCgCCAgCg; SEQ ID NO:1). The reaction was performed in 100 μL volume at 37° C. with timepoints taken at 0, 1, 3, 5 and 10 min. The reaction products were electrophoresed down a denaturing (8 M urea) 20% polyacrylamide gel and imaged on a typhoon phosphorimager. Complete single base extension was seen in 1 minute indicating efficient polymerase incorporation (disulfide linker gel,FIG. 3 ). A second set of lanes is shown in which the material is exposed to DTT after the incorporation. A different band shift can be seen which shows removal of the dye from the DNA construct, thus a cycle of polymerase incorporation and cleavage has been shown using this disulfide compound. -
- 5-[-9-[9-(fluorenyl-methyloxycarbonyl)amino]xanthen-3-yl]valeric acid, (42.8 mg, 80 μmop was stirred at room temperature with disuccinimidyl carbonate (22.5 mg, 88 μmop and N,N-dimethyl aminopyridine (10.8 mg, 88 μmop in DMF. After 5 minutes, mono-5-carboxy TMR ethylene diamine (198.9 mg, 40 μmop was added followed by DIPEA (13.9 μl, 80 μmol). The reaction was stirred at room temperature. After 2 hrs, the reaction mixture was diluted with dichloromethane (100 mL) and the resulting solution was extracted with 1 M aqueous potassium dihydrogen phosphate (50 mL). The DCM layer was separated and evaporated under reduced pressure. The residue was purified by a short column chromatography. The fractions eluting with 40% methanol in chloroform were collected and evaporated under reduced pressure. The residue was then dissolved in dry DMF (1 mL) and N-(2-mercaptoethyl)aminomethyl polystyrene (200 mg, 400 μmop and DBU (12 μl, 80 μmol). After 10 minutes at room temperature, the resins were filtered off and rinsed with dry DMF (1 mL). All the filtrates were combined and then added to a solution of succinic anhydride (80 mg, 800 μmol), DIPEA (139 μl, 800 μmop and DMAP (9.8 mg, 80 μmol) in DMF (1 mL). The reaction mixture was then stirred at room temperature. After overnight (16 hrs), all the solvents were evaporated under reduced pressure and the residue was purified by a short column chromatography. The title compound eluted with 30% methanol in chloroform was obtained as purple powders (22 mg, overall yield 63%). 1HNMR [D6-DMSO]: 8.82 (1H, t, J 5.4, ex.), 8.75 (1H, d, J 8.9, ex.), 8.42 (1H, d, J 1.5), 8.20 (1H, dd, J 8.0 and 1.5), 7.95 (1H, t, J 5.9, ex.), 7.34 (1H, d, J 7.3), 7.30-7.27 (2H, m), 7.21 (1H, d, J 8.5), 7.16-7.07 (2H, m), 6.68 (1H, dd, J 8.8 and 2.5), 6.65 (1H, d, J 2.4), 6.49-6.43 (6H, m), 6.18 (1H, d, J 5.6), 3.95 (1H, t, J 5.9), 3.39-3.36 (2H, m), 3.30-3.27 (2H, m), 2.92 (12H, s), 2.37-2.33 (2H, m), 2.14 (2H, t, J 7.2) and 1.70-1.62 (4H, m). MS[(ES(+)], m/z 868.5 (MH+).
-
- TMR-sieber linker free acid (4.34 mg, 5 μmop was stirred with disuccinimidyl carbonate (1.74 mg, 7.5 μmol) and N,N-dimethyl aminopyridine (0.92 mg, 7.5 μmol) in DMF (1 mL) at room temperature. After 10 minutes, all the reaction mixture was added to tetra-(tri-butylammonium) salt of 5-(3-aminopropynyl)-2′-deoxyuridine-5′-triphosphate (10 μmol). The reaction was stirred at room temperature for 4 hrs and stored in the fridge overnight. The reaction mixture was then diluted with chilled water (10 mL) and all the resulting solution was applied onto a short column of DEAE A-25. The column was initially eluted with 0.1 M TEAB buffer and then 0.7 M TEAB buffer. The 0.7 M TEAB eluents were collected and evaporated under reduced pressure. The residue was co-evaporated with MeOH (2×10 mL) and then purified by preparative HPLC. The title compound was obtained as triethylammonium salt in 31% yield (based on the quantification of TMR at 555 nm in water (pH 7)). 1HNMR in D2O indicated two diastereoisomers, due to the sieber linker moiety and there were approximately three triethylammonium count ions. 1HNMR [D2O]: 8.18 (1H, m), 8.06 (1H, m), 7.76 (0.55H, s), 7.74 (0.45H, s), 7.36-7.09 (5H, m), 6.89-6.72 (3H, m), 6.59-6.37 (5H, m), 6.12 (0.55H, t, J 6.6), 6.05 (0.45H, t, J 6.6), 5.99 (0.45H, d, J 2.5), 5.91 (1.1H, m), 5.88 (0.45H, s), 4.49 (0.55H, m), 4.43 (0.45H, m), 4.00-3.35 (9H, m), 3.30-2.95 (32H, m), 2.65-2.52 (4H, m), 2.25-2.05 (4H, m), 1.62-1.42 (4H, m) and 1.23 (27H, t, J 7.3). 31P [D2O]: −9.91 CP, d, J 19.2), [−11.08 (αP, d, J 20.1) and −11.30 (αP, d, J 20.1), due to two diastereoisomers] and −22.57 (βP, m). MS[(ES(−)], m/z 1369.1 (M−).
- Triphosphate (3) was successfully incorporated using Klenow DNA polymerase. The reaction was performed in the following conditions: 50 mM Tris.HCl (pH 7.5), 10 mM NaCl, 2 mM DTT, 0.1 mM EDTA, 5 mM MgCl2, 2
μM compound 3, 100 nM DNA template (previously labelled with P32 and T4 polynucleotide kinase) and 10 units of commercial exo-Klenow (Amersham Corp. Arlington Heights, Ill., USA). The DNA templates were self-complementary hairpins (5′-TACCgTCgACgTCgACgCTggCg-AgCgTgCTgCggTTTTT(C6-amino)TTACCgCAgCACgCTCgCCAgCg; SEQ ID NO:1). The reaction was performed in 100 μL volume at 37° C. with timepoints taken at 0, 1, 3, 5 and 10 min. The reaction products were electrophoresed down a denaturing (8 M urea) 20% polyacrylamide gel and imaged on a typhoon phosphorimager. Complete single base extension was seen in 1 minute indicating efficient polymerase incorporation (Sieber linker gel,FIG. 4 ). -
- Triphosphate (4) was successfully incorporated using Klenow DNA polymerase. The reaction was performed in the following conditions: 50 mM Tris.HCl (pH 7.5), 10 mM NaCl, 2 mM DTT, 0.1 mM EDTA, 5 mM MgCl2, 2
μM compound 3, 100 nM DNA template (previously labelled with P32 and T4 polynucleotide kinase) and 10 units of commercial exo-Klenow (Amersham Corp., Arlington Heights, Ill., USA). The DNA templates were self-complementary hairpins (5′-TACCgTCgACgTCgACgCTggCg-AgCgTgCTgCggTTTTT(C6-amino)TTACCgCAgCACgCTCgCCAgCg; SEQ ID NO:1). The reaction was performed in 100 μL volume at 37° C. with timepoints taken at 0, 1, 3, 5 and 10 min. The reaction products were electrophoresed down a denaturing (8 M urea) 20% polyacrylamide gel and imaged on a typhoon phosphorimager. Complete single base extension was seen in 1 minute indicating efficient polymerase incorporation (indole linker gel,FIG. 5 ). - All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (21)
1.-25. (canceled)
26. A method for determining the sequence of a target single stranded polynucleotide, comprising:
a) providing four different types of nucleotides, wherein each of the nucleotides comprises: a 3′-hydroxyl group and a base that is linked to a detectable label via a cleavable linker; wherein the detectable label and the cleavable linker block the incorporation of a further nucleotide into a growing polynucleotide strand, wherein the detectable label linked to each nucleotide can be distinguished upon detection from the detectable label used for the other three nucleotides;
b) incorporating one nucleotide from step a) into a complementary strand of the target single stranded polynucleotide;
c) removing non-incorporated nucleotides;
d) detecting the detectable label of the incorporated nucleotide of step b), thereby determining the type of nucleotide incorporated; and
e) removing the detectable label of the incorporated nucleotide of step b).
27. The method of claim 26 , further comprising: repeating steps a)-e) one or more times, thereby determining the sequence of the target single stranded polynucleotide.
28. The method of claim 26 , wherein the target single-stranded polynucleotide is immobilized on a solid support.
29. The method of claim 26 , wherein each of the nucleotides for incorporation is a deoxyribonucleotide triphosphate.
30. The method of claim 29 , wherein the base is a purine or a pyrimidine.
31. The method of claim 30 , wherein the base is a deazapurine.
32. The method of claim 26 , wherein the detectable label is a fluorophore.
33. The method of claim 26 , wherein the linker is an acid labile linker or a photolabile linker.
34. The method of claim 33 , wherein the linker comprises an azido moiety or a disulfide linkage.
35. The method of claim 26 , wherein the incorporation of the nucleotide is accomplished by a terminal polymerase, a terminal transferase, or a reverse transcriptase.
36. The method of claim 35 , wherein the incorporation of the nucleotides is accomplished by a terminal polymerase.
37. A method of labelling a nucleic acid molecule, the method comprising incorporating a nucleotide into the nucleic acid molecule, wherein the nucleotide comprises: a 3′-hydroxyl group and a base that is linked to a detectable label via a cleavable linker; wherein the detectable label and the cleavable linker block the incorporation of a further nucleotide into the nucleic acid molecule.
38. A kit comprising:
a) four individual nucleotides, wherein each nucleotide comprises a 3′-hydroxyl group and a base that is linked to a detectable label via a cleavable linker, wherein the detectable label and the cleavable linker block the incorporation of a further nucleotide into a growing polynucleotide strand, and wherein the detectable label linked to each nucleotide can be distinguished upon detection from the detectable label used for the other three nucleotides; and
b) packaging materials therefor.
39. The kit of claim 38 , wherein two or more of the individual nucleotides are mixed.
40. The kit of claim 38 , wherein each of the nucleotides is a deoxyribonucleotide triphosphate.
41. The kit of claim 40 , wherein the base is purine, deazapurine, or pyrimidine.
42. The kit of claim 38 , wherein the detectable label is a fluorophore.
43. The kit of claim 38 , wherein the linker is an acid labile linker or a photolabile linker.
44. The kit of claim 43 , wherein the linker comprises an azido moiety or a disulfide linkage.
45. The kit of claim 38 , further comprising a polymerase and a buffer appropriate for the action of the polymerase.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/593,512 US20200109448A1 (en) | 2001-12-04 | 2019-10-04 | Labelled nucleotides |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0129012.1A GB0129012D0 (en) | 2001-12-04 | 2001-12-04 | Labelled nucleotides |
GB0129012.1 | 2001-12-04 | ||
US10/227,131 US7057026B2 (en) | 2001-12-04 | 2002-08-23 | Labelled nucleotides |
US11/301,578 US7566537B2 (en) | 2001-12-04 | 2005-12-13 | Labelled nucleotides |
US12/460,741 US7785796B2 (en) | 2001-12-04 | 2009-07-23 | Labelled nucleotides |
US12/804,296 US8148064B2 (en) | 2001-12-04 | 2010-07-19 | Labelled nucleotides |
US13/432,989 US8394586B2 (en) | 2001-12-04 | 2012-03-28 | Labelled nucleotides |
US13/791,597 US9388463B2 (en) | 2001-12-04 | 2013-03-08 | Labelled nucleotides |
US14/857,671 US9410200B2 (en) | 2001-12-04 | 2015-09-17 | Labelled nucleotides |
US15/202,456 US10480025B2 (en) | 2001-12-04 | 2016-07-05 | Labelled nucleotides |
US15/354,511 US20170067104A1 (en) | 2001-12-04 | 2016-11-17 | Labelled nucleotides |
US16/593,512 US20200109448A1 (en) | 2001-12-04 | 2019-10-04 | Labelled nucleotides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/354,511 Division US20170067104A1 (en) | 2001-12-04 | 2016-11-17 | Labelled nucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200109448A1 true US20200109448A1 (en) | 2020-04-09 |
Family
ID=9926979
Family Applications (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/283,285 Expired - Lifetime US7772384B2 (en) | 2001-12-04 | 2008-09-09 | Labelled nucleotides |
US12/804,025 Expired - Fee Related US8158346B2 (en) | 2001-12-04 | 2010-07-13 | Labelled nucleotides |
US12/804,296 Expired - Fee Related US8148064B2 (en) | 2001-12-04 | 2010-07-19 | Labelled nucleotides |
US13/432,989 Expired - Lifetime US8394586B2 (en) | 2001-12-04 | 2012-03-28 | Labelled nucleotides |
US13/437,772 Abandoned US20120252010A1 (en) | 2001-12-04 | 2012-04-02 | Labelled nucleotides |
US13/791,597 Expired - Fee Related US9388463B2 (en) | 2001-12-04 | 2013-03-08 | Labelled nucleotides |
US14/094,646 Expired - Fee Related US9121062B2 (en) | 2001-12-04 | 2013-12-02 | Labelled nucleotides |
US14/821,566 Expired - Lifetime US9605310B2 (en) | 2001-12-04 | 2015-08-07 | Labelled nucleotides |
US14/857,671 Expired - Fee Related US9410200B2 (en) | 2001-12-04 | 2015-09-17 | Labelled nucleotides |
US15/202,456 Expired - Fee Related US10480025B2 (en) | 2001-12-04 | 2016-07-05 | Labelled nucleotides |
US15/354,511 Abandoned US20170067104A1 (en) | 2001-12-04 | 2016-11-17 | Labelled nucleotides |
US15/470,801 Expired - Fee Related US10519496B2 (en) | 2001-12-04 | 2017-03-27 | Labelled nucleotides |
US16/593,512 Abandoned US20200109448A1 (en) | 2001-12-04 | 2019-10-04 | Labelled nucleotides |
US16/726,040 Abandoned US20200115747A1 (en) | 2001-12-04 | 2019-12-23 | Labelled nucleotides |
Family Applications Before (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/283,285 Expired - Lifetime US7772384B2 (en) | 2001-12-04 | 2008-09-09 | Labelled nucleotides |
US12/804,025 Expired - Fee Related US8158346B2 (en) | 2001-12-04 | 2010-07-13 | Labelled nucleotides |
US12/804,296 Expired - Fee Related US8148064B2 (en) | 2001-12-04 | 2010-07-19 | Labelled nucleotides |
US13/432,989 Expired - Lifetime US8394586B2 (en) | 2001-12-04 | 2012-03-28 | Labelled nucleotides |
US13/437,772 Abandoned US20120252010A1 (en) | 2001-12-04 | 2012-04-02 | Labelled nucleotides |
US13/791,597 Expired - Fee Related US9388463B2 (en) | 2001-12-04 | 2013-03-08 | Labelled nucleotides |
US14/094,646 Expired - Fee Related US9121062B2 (en) | 2001-12-04 | 2013-12-02 | Labelled nucleotides |
US14/821,566 Expired - Lifetime US9605310B2 (en) | 2001-12-04 | 2015-08-07 | Labelled nucleotides |
US14/857,671 Expired - Fee Related US9410200B2 (en) | 2001-12-04 | 2015-09-17 | Labelled nucleotides |
US15/202,456 Expired - Fee Related US10480025B2 (en) | 2001-12-04 | 2016-07-05 | Labelled nucleotides |
US15/354,511 Abandoned US20170067104A1 (en) | 2001-12-04 | 2016-11-17 | Labelled nucleotides |
US15/470,801 Expired - Fee Related US10519496B2 (en) | 2001-12-04 | 2017-03-27 | Labelled nucleotides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/726,040 Abandoned US20200115747A1 (en) | 2001-12-04 | 2019-12-23 | Labelled nucleotides |
Country Status (2)
Country | Link |
---|---|
US (14) | US7772384B2 (en) |
GB (1) | GB0129012D0 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10982277B2 (en) | 2013-03-15 | 2021-04-20 | Illumina Cambridge Limited | Modified nucleosides or nucleotides |
US10995111B2 (en) | 2003-08-22 | 2021-05-04 | Illumina Cambridge Limited | Labelled nucleotides |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9708358B2 (en) | 2000-10-06 | 2017-07-18 | The Trustees Of Columbia University In The City Of New York | Massive parallel method for decoding DNA and RNA |
ATE356222T1 (en) | 2000-10-06 | 2007-03-15 | Univ Columbia | MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA |
GB0129012D0 (en) | 2001-12-04 | 2002-01-23 | Solexa Ltd | Labelled nucleotides |
US7414116B2 (en) | 2002-08-23 | 2008-08-19 | Illumina Cambridge Limited | Labelled nucleotides |
DK3363809T3 (en) | 2002-08-23 | 2020-05-04 | Illumina Cambridge Ltd | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCE |
GB0517097D0 (en) * | 2005-08-19 | 2005-09-28 | Solexa Ltd | Modified nucleosides and nucleotides and uses thereof |
WO2007053719A2 (en) | 2005-10-31 | 2007-05-10 | The Trustees Of Columbia University In The City Of New York | Chemically cleavable 3'-o-allyl-dntp-allyl-fluorophore fluorescent nucleotide analogues and related methods |
GB2446084B (en) | 2005-10-31 | 2011-03-02 | Univ Columbia | Synthesis of four color 3-o-allyl modified photocleavable fluorescent nucleotides and related methods |
GB2457402B (en) | 2006-12-01 | 2011-10-19 | Univ Columbia | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators |
US11940413B2 (en) | 2007-02-05 | 2024-03-26 | IsoPlexis Corporation | Methods and devices for sequencing nucleic acids in smaller batches |
EP3431615A3 (en) | 2007-10-19 | 2019-02-20 | The Trustees of Columbia University in the City of New York | Dna sequencing with non-fluorescent nucleotide reversible terminators cleavable label modified nucleotide terminators |
US9187783B2 (en) | 2010-10-04 | 2015-11-17 | Genapsys, Inc. | Systems and methods for automated reusable parallel biological reactions |
US9184099B2 (en) | 2010-10-04 | 2015-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Biosensor devices, systems and methods therefor |
US9399217B2 (en) | 2010-10-04 | 2016-07-26 | Genapsys, Inc. | Chamber free nanoreactor system |
WO2013082164A1 (en) | 2011-11-28 | 2013-06-06 | Life Technologies Corporation | Enhanced ligation reactions |
US8585973B2 (en) | 2011-05-27 | 2013-11-19 | The Board Of Trustees Of The Leland Stanford Junior University | Nano-sensor array |
US9926596B2 (en) | 2011-05-27 | 2018-03-27 | Genapsys, Inc. | Systems and methods for genetic and biological analysis |
US9453258B2 (en) | 2011-09-23 | 2016-09-27 | Illumina, Inc. | Methods and compositions for nucleic acid sequencing |
WO2013082619A1 (en) * | 2011-12-01 | 2013-06-06 | Genapsys, Inc. | Systems and methods for high efficiency electronic sequencing and detection |
US9150896B2 (en) | 2012-09-06 | 2015-10-06 | Illumina, Inc. | Nucleotides and primers with removable blocking groups |
US10829816B2 (en) | 2012-11-19 | 2020-11-10 | Apton Biosystems, Inc. | Methods of analyte detection |
US10378053B2 (en) | 2017-03-17 | 2019-08-13 | Apton Biosystems, Inc. | Sequencing and high resolution imaging |
JP6395718B2 (en) | 2012-11-19 | 2018-09-26 | アプトン バイオシステムズ インコーポレイテッド | Method for digital analysis of molecular analytes using single molecule detection |
WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
US9146248B2 (en) | 2013-03-14 | 2015-09-29 | Intelligent Bio-Systems, Inc. | Apparatus and methods for purging flow cells in nucleic acid sequencing instruments |
US9809852B2 (en) | 2013-03-15 | 2017-11-07 | Genapsys, Inc. | Systems and methods for biological analysis |
US9255265B2 (en) | 2013-03-15 | 2016-02-09 | Illumina, Inc. | Methods for producing stranded cDNA libraries |
US9591268B2 (en) | 2013-03-15 | 2017-03-07 | Qiagen Waltham, Inc. | Flow cell alignment methods and systems |
US9771613B2 (en) | 2013-04-02 | 2017-09-26 | Molecular Assemblies, Inc. | Methods and apparatus for synthesizing nucleic acid |
US9279149B2 (en) | 2013-04-02 | 2016-03-08 | Molecular Assemblies, Inc. | Methods and apparatus for synthesizing nucleic acids |
US8808989B1 (en) | 2013-04-02 | 2014-08-19 | Molecular Assemblies, Inc. | Methods and apparatus for synthesizing nucleic acids |
US10683536B2 (en) | 2013-04-02 | 2020-06-16 | Molecular Assemblies, Inc. | Reusable initiators for synthesizing nucleic acids |
US11331643B2 (en) | 2013-04-02 | 2022-05-17 | Molecular Assemblies, Inc. | Reusable initiators for synthesizing nucleic acids |
US11384377B2 (en) | 2013-04-02 | 2022-07-12 | Molecular Assemblies, Inc. | Reusable initiators for synthesizing nucleic acids |
US20160201119A1 (en) | 2013-08-22 | 2016-07-14 | Apton Biosystems, Inc. | Digital Analysis of Molecular Analytes Using Electrical Methods |
US10125393B2 (en) | 2013-12-11 | 2018-11-13 | Genapsys, Inc. | Systems and methods for biological analysis and computation |
FR3020071B1 (en) | 2014-04-17 | 2017-12-22 | Dna Script | PROCESS FOR THE SYNTHESIS OF NUCLEIC ACIDS, IN PARTICULAR LARGE NUCLEIC ACIDS, USE OF THE METHOD AND KIT FOR IMPLEMENTING THE METHOD |
EP3132060B1 (en) | 2014-04-18 | 2019-03-13 | Genapsys Inc. | Methods and systems for nucleic acid amplification |
SG11201609692SA (en) | 2014-06-03 | 2016-12-29 | Illumina Inc | Compositions, systems, and methods for detecting events using tethers anchored to or adjacent to nanopores |
FR3025201B1 (en) | 2014-09-02 | 2018-10-12 | Dna Script | MODIFIED NUCLEOTIDES FOR THE SYNTHESIS OF NUCLEIC ACIDS, A KIT COMPRISING SUCH NUCLEOTIDES AND THEIR USE FOR GENERATING SYNTHETIC NUCLEIC ACID GENES OR SEQUENCES |
US10487357B2 (en) | 2014-10-03 | 2019-11-26 | Life Technologies Corporation | Methods of nucleic acid analysis using terminator nucleotides |
US10544455B2 (en) | 2014-10-03 | 2020-01-28 | Life Technologies Corporation | Sequencing methods, compositions and systems using terminator nucleotides |
US10774316B2 (en) | 2014-10-20 | 2020-09-15 | Molecular Assemblies, Inc. | Modified template-independent enzymes for polydeoxynucleotide synthesis |
US10059929B2 (en) | 2014-10-20 | 2018-08-28 | Molecular Assemblies, Inc. | Modified template-independent enzymes for polydeoxynucleotide synthesis |
US11390858B2 (en) | 2014-10-20 | 2022-07-19 | Molecular Assemblies, Inc. | Modified template-independent enzymes for polydeoxynucleotide synthesis |
CN107074904B (en) | 2014-10-23 | 2022-12-23 | 深圳华大智造科技股份有限公司 | Signal-constrained sequencing (SCS) and nucleotide analogs for signal-constrained sequencing |
US10485757B2 (en) | 2015-01-27 | 2019-11-26 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
WO2016201142A1 (en) | 2015-06-09 | 2016-12-15 | Life Technologies Corporation | Methods, systems, compositions, kits, apparatus and computer-readable media for molecular tagging |
WO2017058953A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Design and synthesis of novel disulfide linker based nucleotides as reversible terminators for dna sequencing by synthesis |
WO2017079498A2 (en) | 2015-11-06 | 2017-05-11 | Intelligent Biosystems, Inc. | Nucleotide analogues |
CN116656795A (en) | 2016-05-23 | 2023-08-29 | 纽约哥伦比亚大学董事会 | Nucleotide derivatives and methods of use thereof |
CN115820806A (en) | 2016-06-16 | 2023-03-21 | 哈斯达克科学公司 | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules |
CN109790575A (en) | 2016-07-20 | 2019-05-21 | 吉纳普赛斯股份有限公司 | System and method for nucleic acid sequencing |
WO2018081113A1 (en) | 2016-10-24 | 2018-05-03 | Sawaya Sterling | Concealing information present within nucleic acids |
US11466318B2 (en) | 2016-12-27 | 2022-10-11 | Egi Tech (Shen Zhen) Co., Limited | Single fluorescent dye-based sequencing method |
JP6885576B2 (en) * | 2017-01-19 | 2021-06-16 | 株式会社日立ハイテクサイエンス | Charged particle beam device |
US11591647B2 (en) | 2017-03-06 | 2023-02-28 | Singular Genomics Systems, Inc. | Nucleic acid sequencing-by-synthesis (SBS) methods that combine SBS cycle steps |
US12018325B2 (en) | 2017-03-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | 3′-O-modified nucleotide analogues with different cleavable linkers for attaching fluorescent labels to the base for DNA sequencing by synthesis |
CN110785497A (en) | 2017-04-23 | 2020-02-11 | 伊鲁米纳剑桥有限公司 | Compositions and methods for improving sample identification in indexed nucleic acid libraries |
EP3615671B1 (en) | 2017-04-23 | 2021-07-21 | Illumina Cambridge Limited | Compositions and methods for improving sample identification in indexed nucleic acid libraries |
FI3842545T3 (en) | 2017-04-23 | 2023-01-31 | Compositions and methods for improving sample identification in indexed nucleic acid libraries | |
EP3619340A4 (en) | 2017-05-02 | 2021-01-20 | Haystack Sciences Corporation | Molecules for verifying oligonucleotide directed combinatorial synthesis and methods of making and using the same |
GB2578038B (en) | 2017-06-16 | 2022-11-23 | Life Technologies Corp | Control nucleic acids, and compositions, kits, and uses thereof |
CA3070991C (en) | 2017-06-19 | 2023-10-17 | Massachusetts Institute Of Technology | Automated methods for scalable, parallelized enzymatic biopolymer synthesis and modification using microfluidic devices |
US11993813B2 (en) | 2017-08-31 | 2024-05-28 | Mgi Tech Co., Ltd. | Nucleic acid probe and nucleic acid sequencing method |
CA3076378A1 (en) | 2017-09-21 | 2019-03-28 | Genapsys, Inc. | Systems and methods for nucleic acid sequencing |
CN110691854B (en) * | 2017-10-25 | 2023-09-12 | 深圳华大生命科学研究院 | Nucleic acid sequencing method and nucleic acid sequencing kit |
WO2020061237A1 (en) | 2018-09-19 | 2020-03-26 | Apton Biosystems, Inc. | Densely-packed analyte layers and detection methods |
US20230028359A1 (en) | 2018-10-25 | 2023-01-26 | Singular Genomics Systems, Inc. | Nucleotide analogues |
US10876148B2 (en) | 2018-11-14 | 2020-12-29 | Element Biosciences, Inc. | De novo surface preparation and uses thereof |
US10768173B1 (en) | 2019-09-06 | 2020-09-08 | Element Biosciences, Inc. | Multivalent binding composition for nucleic acid analysis |
US10704094B1 (en) | 2018-11-14 | 2020-07-07 | Element Biosciences, Inc. | Multipart reagents having increased avidity for polymerase binding |
GB2588716B (en) | 2018-12-07 | 2023-11-01 | Element Biosciences Inc | Flow cell device and use thereof |
WO2020120442A2 (en) | 2018-12-13 | 2020-06-18 | Dna Script | Direct oligonucleotide synthesis on cells and biomolecules |
US11440933B2 (en) | 2018-12-19 | 2022-09-13 | Roche Sequencing Solutions, Inc. | 3′ protected nucleotides |
EP3908286A4 (en) | 2019-01-08 | 2022-10-12 | Singular Genomics Systems, Inc. | Nucleotide cleavable linkers and uses thereof |
JP7538807B2 (en) | 2019-02-12 | 2024-08-22 | ディーエヌエー スクリプト | Efficient product cleavage in template-free enzymatic polynucleotide synthesis. |
JP2022521730A (en) * | 2019-02-19 | 2022-04-12 | ウルティマ・ゲノミクス・インコーポレーテッド | Linkers and methods for photodetection and sequencing |
US11609208B2 (en) | 2019-04-12 | 2023-03-21 | Western Digital Technologies, Inc. | Devices and methods for molecule detection based on thermal stabilities of magnetic nanoparticles |
US11327073B2 (en) | 2019-04-12 | 2022-05-10 | Western Digital Technologies, Inc. | Thermal sensor array for molecule detection and related detection schemes |
US11738336B2 (en) | 2019-04-12 | 2023-08-29 | Western Digital Technologies, Inc. | Spin torque oscillator (STO) sensors used in nucleic acid sequencing arrays and detection schemes for nucleic acid sequencing |
US11579217B2 (en) | 2019-04-12 | 2023-02-14 | Western Digital Technologies, Inc. | Devices and methods for frequency- and phase-based detection of magnetically-labeled molecules using spin torque oscillator (STO) sensors |
US11112468B2 (en) | 2019-04-12 | 2021-09-07 | Western Digital Technologies, Inc. | Magnetoresistive sensor array for molecule detection and related detection schemes |
US11208682B2 (en) | 2019-09-13 | 2021-12-28 | Western Digital Technologies, Inc. | Enhanced optical detection for nucleic acid sequencing using thermally-dependent fluorophore tags |
US11287422B2 (en) | 2019-09-23 | 2022-03-29 | Element Biosciences, Inc. | Multivalent binding composition for nucleic acid analysis |
JP2022549196A (en) | 2019-09-23 | 2022-11-24 | ディーエヌエー スクリプト | Increased Yields of Long Sequences in Templateless Enzymatic Synthesis of Polynucleotides |
US11747329B2 (en) | 2019-11-22 | 2023-09-05 | Western Digital Technologies, Inc. | Magnetic gradient concentrator/reluctance detector for molecule detection |
JP7500727B2 (en) | 2019-12-18 | 2024-06-17 | エフ. ホフマン-ラ ロシュ アーゲー | Sequencing-by-synthesis method using sequential labeling schemes |
US11807851B1 (en) | 2020-02-18 | 2023-11-07 | Ultima Genomics, Inc. | Modified polynucleotides and uses thereof |
US20230203592A1 (en) | 2020-05-05 | 2023-06-29 | Akershus Universitetssykehus Hf | Compositions and methods for characterizing bowel cancer |
EP4200444A4 (en) | 2020-10-30 | 2024-09-25 | Singular Genomics Systems Inc | Methods and compositions for reducing nucleotide impurities |
WO2024098185A1 (en) * | 2022-11-07 | 2024-05-16 | GeneSense Technology Inc., Shanghai (CN) | Nucleic acid sequencing using self-luminescence |
CN117645636B (en) * | 2024-01-30 | 2024-04-16 | 深圳赛陆医疗科技有限公司 | Preparation method of adenine azide intermediate |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) * | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
US5175269A (en) * | 1984-01-30 | 1992-12-29 | Enzo Diagnostics, Inc. | Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group |
US5118605A (en) * | 1984-10-16 | 1992-06-02 | Chiron Corporation | Polynucleotide determination with selectable cleavage sites |
US4824775A (en) * | 1985-01-03 | 1989-04-25 | Molecular Diagnostics, Inc. | Cells labeled with multiple Fluorophores bound to a nucleic acid carrier |
US4772691A (en) * | 1985-06-05 | 1988-09-20 | The Medical College Of Wisconsin, Inc. | Chemically cleavable nucleotides |
US4863849A (en) * | 1985-07-18 | 1989-09-05 | New York Medical College | Automatable process for sequencing nucleotide |
US4888274A (en) | 1985-09-18 | 1989-12-19 | Yale University | RecA nucleoprotein filament and methods |
US5047519A (en) | 1986-07-02 | 1991-09-10 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
US5242796A (en) | 1986-07-02 | 1993-09-07 | E. I. Du Pont De Nemours And Company | Method, system and reagents for DNA sequencing |
GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
SE8801070D0 (en) | 1988-03-23 | 1988-03-23 | Pharmacia Ab | METHOD FOR IMMOBILIZING A DNA SEQUENCE ON A SOLID SUPPORT |
US4971903A (en) | 1988-03-25 | 1990-11-20 | Edward Hyman | Pyrophosphate-based method and apparatus for sequencing nucleic acids |
US5174962A (en) * | 1988-06-20 | 1992-12-29 | Genomyx, Inc. | Apparatus for determining DNA sequences by mass spectrometry |
GB8910880D0 (en) | 1989-05-11 | 1989-06-28 | Amersham Int Plc | Sequencing method |
US6346413B1 (en) * | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
US5547839A (en) * | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5302509A (en) * | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
CA2044616A1 (en) | 1989-10-26 | 1991-04-27 | Roger Y. Tsien | Dna sequencing |
WO1993005183A1 (en) | 1991-09-09 | 1993-03-18 | Baylor College Of Medicine | Method and device for rapid dna or rna sequencing determination by a base addition sequencing scheme |
DE4141178A1 (en) | 1991-12-13 | 1993-06-17 | Europ Lab Molekularbiolog | New nucleic acid sequencing method - using one labelled nucleotide at one time in cycles comprising elongation, wash, label detection and removal of the label, then repeating |
GB9208733D0 (en) * | 1992-04-22 | 1992-06-10 | Medical Res Council | Dna sequencing method |
GB9210176D0 (en) * | 1992-05-12 | 1992-06-24 | Cemu Bioteknik Ab | Chemical method |
US5436143A (en) * | 1992-12-23 | 1995-07-25 | Hyman; Edward D. | Method for enzymatic synthesis of oligonucleotides |
US5516664A (en) | 1992-12-23 | 1996-05-14 | Hyman; Edward D. | Enzymatic synthesis of repeat regions of oligonucleotides |
US6074823A (en) * | 1993-03-19 | 2000-06-13 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
FR2703052B1 (en) * | 1993-03-26 | 1995-06-02 | Pasteur Institut | New method of nucleic acid sequencing. |
US5959089A (en) | 1993-07-19 | 1999-09-28 | Hannessian; Stephen | Amino-cyclodextrin syntheses |
GB9315847D0 (en) * | 1993-07-30 | 1993-09-15 | Isis Innovation | Tag reagent and assay method |
US5547859A (en) * | 1993-08-02 | 1996-08-20 | Goodman; Myron F. | Chain-terminating nucleotides for DNA sequencing methods |
EP0765401B1 (en) * | 1993-11-17 | 2001-02-21 | Amersham Pharmacia Biotech UK Limited | Primer extension mass spectroscopy nucleic acid sequencing method |
US6232465B1 (en) * | 1994-09-02 | 2001-05-15 | Andrew C. Hiatt | Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides |
US6214987B1 (en) * | 1994-09-02 | 2001-04-10 | Andrew C. Hiatt | Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides |
US5872244A (en) | 1994-09-02 | 1999-02-16 | Andrew C. Hiatt | 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds |
US5763594A (en) * | 1994-09-02 | 1998-06-09 | Andrew C. Hiatt | 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds |
US5808045A (en) * | 1994-09-02 | 1998-09-15 | Andrew C. Hiatt | Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides |
US6013445A (en) | 1996-06-06 | 2000-01-11 | Lynx Therapeutics, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
US5604097A (en) | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
CA2202480A1 (en) | 1994-10-14 | 1996-04-25 | Jane Charlotte Moores | Porphyrin labeling of polynucleotides |
US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
DE4438918A1 (en) * | 1994-11-04 | 1996-05-09 | Hoechst Ag | Modified oligonucleotides, their preparation and their use |
SE9500342D0 (en) | 1995-01-31 | 1995-01-31 | Marek Kwiatkowski | Novel chain terminators, the use thereof for nucleic acid sequencing and synthesis and a method of their preparation |
AU5171696A (en) | 1995-02-27 | 1996-09-18 | Ely Michael Rabani | Device, compounds, algorithms, and methods of molecular characterization and manipulation with molecular parallelism |
EP0745686A1 (en) * | 1995-06-01 | 1996-12-04 | Roche Diagnostics GmbH | The use of DNA polymerase 3'-intrinsic editing activity |
US5728528A (en) * | 1995-09-20 | 1998-03-17 | The Regents Of The University Of California | Universal spacer/energy transfer dyes |
US6613508B1 (en) * | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
US6312893B1 (en) * | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
EP0992511B1 (en) | 1996-01-23 | 2009-03-11 | Operon Biotechnologies, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
US5821356A (en) * | 1996-08-12 | 1998-10-13 | The Perkin Elmer Corporation | Propargylethoxyamino nucleotides |
US5885775A (en) * | 1996-10-04 | 1999-03-23 | Perseptive Biosystems, Inc. | Methods for determining sequences information in polynucleotides using mass spectrometry |
JP2001508657A (en) | 1997-01-08 | 2001-07-03 | プロリゴ・エルエルシー | Oligonucleotide bioconjugation |
US6046005A (en) | 1997-01-15 | 2000-04-04 | Incyte Pharmaceuticals, Inc. | Nucleic acid sequencing with solid phase capturable terminators comprising a cleavable linking group |
US6136543A (en) * | 1997-01-31 | 2000-10-24 | Hitachi, Ltd. | Method for determining nucleic acids base sequence and apparatus therefor |
DK1017848T3 (en) | 1997-07-28 | 2003-02-10 | Medical Biosystems Ltd | Nucleic acid sequence analysis |
US6008379A (en) * | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
US6485944B1 (en) * | 1997-10-10 | 2002-11-26 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
US6511803B1 (en) | 1997-10-10 | 2003-01-28 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
EP1028970A1 (en) | 1997-10-10 | 2000-08-23 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
GB9815163D0 (en) | 1998-07-13 | 1998-09-09 | Brax Genomics Ltd | Compounds |
CA2325399A1 (en) | 1998-03-23 | 1999-09-30 | Invitrogen Corporation | Modified nucleotides and methods useful for nucleic acid sequencing |
US6780591B2 (en) * | 1998-05-01 | 2004-08-24 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
WO1999057321A1 (en) | 1998-05-01 | 1999-11-11 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and dna molecules |
US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
US6218530B1 (en) * | 1998-06-02 | 2001-04-17 | Ambergen Inc. | Compounds and methods for detecting biomolecules |
US6287821B1 (en) * | 1998-06-11 | 2001-09-11 | Orchid Biosciences, Inc. | Nucleotide analogues with 3'-pro-fluorescent fluorophores in nucleic acid sequence analysis |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6218118B1 (en) * | 1998-07-09 | 2001-04-17 | Agilent Technologies, Inc. | Method and mixture reagents for analyzing the nucleotide sequence of nucleic acids by mass spectrometry |
IL141148A0 (en) | 1998-07-30 | 2002-02-10 | Solexa Ltd | Arrayed biomolecules and their use in sequencing |
US6787308B2 (en) * | 1998-07-30 | 2004-09-07 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
GB0002310D0 (en) | 2000-02-01 | 2000-03-22 | Solexa Ltd | Polynucleotide sequencing |
DE19844931C1 (en) | 1998-09-30 | 2000-06-15 | Stefan Seeger | Procedures for DNA or RNA sequencing |
US6221592B1 (en) | 1998-10-20 | 2001-04-24 | Wisconsin Alumi Research Foundation | Computer-based methods and systems for sequencing of individual nucleic acid molecules |
US6451525B1 (en) | 1998-12-03 | 2002-09-17 | Pe Corporation (Ny) | Parallel sequencing method |
WO2000036151A1 (en) | 1998-12-14 | 2000-06-22 | Li-Cor, Inc. | A heterogeneous assay for pyrophosphate detection |
US6380378B1 (en) * | 1998-12-24 | 2002-04-30 | Toagosei Company, Ltd. | Nucleotide compound, nucleotide block oligonucleotide, and method for producing them |
US6087112A (en) | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
EP2177627B1 (en) | 1999-02-23 | 2012-05-02 | Caliper Life Sciences, Inc. | Manipulation of microparticles in microfluidic systems |
US7270951B1 (en) | 1999-03-10 | 2007-09-18 | Asm Scientific, Inc. | Method for direct nucleic acid sequencing |
US7037654B2 (en) * | 1999-04-30 | 2006-05-02 | Aclara Biosciences, Inc. | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
US7056661B2 (en) | 1999-05-19 | 2006-06-06 | Cornell Research Foundation, Inc. | Method for sequencing nucleic acid molecules |
US6818395B1 (en) * | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
AU5956200A (en) | 1999-07-28 | 2001-02-19 | Enzymatics Ltd | An antibiotic and a haloperoxidase produced by an alcaligenes microorganism |
US6242193B1 (en) * | 1999-07-30 | 2001-06-05 | Hitachi, Ltd. | Apparatus for determining base sequence of nucleic acid |
US6982146B1 (en) * | 1999-08-30 | 2006-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | High speed parallel molecular nucleic acid sequencing |
WO2001016375A2 (en) | 1999-08-30 | 2001-03-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High speed parallel molecular nucleic acid sequencing |
AU7537200A (en) | 1999-09-29 | 2001-04-30 | Solexa Ltd. | Polynucleotide sequencing |
US6309836B1 (en) * | 1999-10-05 | 2001-10-30 | Marek Kwiatkowski | Compounds for protecting hydroxyls and methods for their use |
EP1228244A4 (en) | 1999-11-04 | 2005-02-09 | California Inst Of Techn | Methods and apparatuses for analyzing polynucleotide sequences |
AU3015801A (en) * | 1999-12-23 | 2001-07-09 | Axaron Bioscience Ag | Method for carrying out the parallel sequencing of a nucleic acid mixture on a surface |
GB0002389D0 (en) | 2000-02-02 | 2000-03-22 | Solexa Ltd | Molecular arrays |
EP1182267B1 (en) | 2000-03-30 | 2012-01-18 | Toyota Jidosha Kabushiki Kaisha | Method of determining base sequence of single nucleic acid molecule |
GB0013276D0 (en) * | 2000-06-01 | 2000-07-26 | Amersham Pharm Biotech Uk Ltd | Nucleotide analogues |
GB0016473D0 (en) | 2000-07-05 | 2000-08-23 | Amersham Pharm Biotech Uk Ltd | Sequencing method |
DE10041539A1 (en) | 2000-08-24 | 2002-03-07 | Febit Ferrarius Biotech Gmbh | New amidite derivatives for the synthesis of polymers on surfaces |
AU8911101A (en) | 2000-09-11 | 2002-03-26 | Univ Columbia | Combinatorial fluorescence energy transfer tags and uses thereof |
ATE356222T1 (en) * | 2000-10-06 | 2007-03-15 | Univ Columbia | MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA |
AU2002241803A1 (en) | 2000-10-20 | 2002-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Transient electrical signal based methods and devices for characterizing molecular interaction and/or motion in a sample |
US7297518B2 (en) | 2001-03-12 | 2007-11-20 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension |
US20030027140A1 (en) | 2001-03-30 | 2003-02-06 | Jingyue Ju | High-fidelity DNA sequencing using solid phase capturable dideoxynucleotides and mass spectrometry |
DE10120797B4 (en) | 2001-04-27 | 2005-12-22 | Genovoxx Gmbh | Method for analyzing nucleic acid chains |
DE10120798B4 (en) | 2001-04-27 | 2005-12-29 | Genovoxx Gmbh | Method for determining gene expression |
US6613523B2 (en) | 2001-06-29 | 2003-09-02 | Agilent Technologies, Inc. | Method of DNA sequencing using cleavable tags |
CA2452474C (en) * | 2001-07-13 | 2012-03-06 | Ambergen, Inc. | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof |
WO2003020968A2 (en) | 2001-08-29 | 2003-03-13 | Genovoxx Gmbh | Method for analyzing nucleic acid sequences and gene expression |
GB0128526D0 (en) | 2001-11-29 | 2002-01-23 | Amersham Pharm Biotech Uk Ltd | Nucleotide analogues |
US7057026B2 (en) * | 2001-12-04 | 2006-06-06 | Solexa Limited | Labelled nucleotides |
GB0129012D0 (en) | 2001-12-04 | 2002-01-23 | Solexa Ltd | Labelled nucleotides |
US20030180769A1 (en) | 2002-02-05 | 2003-09-25 | Metzker Michael L. | Substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene compounds for 8-color DNA sequencing |
EP1495137B1 (en) | 2002-04-04 | 2005-09-14 | Biotage AB | Primer extension based method employing nucleotides labelled via cleavable linkers |
WO2003087302A2 (en) * | 2002-04-12 | 2003-10-23 | Stratagene | Dual-labeled nucleotides |
US7074597B2 (en) | 2002-07-12 | 2006-07-11 | The Trustees Of Columbia University In The City Of New York | Multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry |
DK3363809T3 (en) | 2002-08-23 | 2020-05-04 | Illumina Cambridge Ltd | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCE |
US7414116B2 (en) | 2002-08-23 | 2008-08-19 | Illumina Cambridge Limited | Labelled nucleotides |
DK3147292T3 (en) | 2002-08-23 | 2018-12-03 | Illumina Cambridge Ltd | LABELED NUCLEOTIDES |
GB0321306D0 (en) | 2003-09-11 | 2003-10-15 | Solexa Ltd | Modified polymerases for improved incorporation of nucleotide analogues |
WO2005084367A2 (en) | 2004-03-03 | 2005-09-15 | The Trustees Of Columbia University In The City Of New York | Photocleavable fluorescent nucleotides for dna sequencing on chip constructed by site-specific coupling chemistry |
US7393533B1 (en) | 2004-11-08 | 2008-07-01 | La Jolla Institute For Allergy And Immunology | H3L envelope protein immunization methods and H3L envelope passive protection methods |
GB0517097D0 (en) | 2005-08-19 | 2005-09-28 | Solexa Ltd | Modified nucleosides and nucleotides and uses thereof |
US8481259B2 (en) | 2007-02-05 | 2013-07-09 | Intelligent Bio-Systems, Inc. | Methods and devices for sequencing nucleic acids in smaller batches |
US8612161B2 (en) | 2008-03-19 | 2013-12-17 | Intelligent Biosystems Inc. | Methods and compositions for base calling nucleic acids |
EP3431615A3 (en) | 2007-10-19 | 2019-02-20 | The Trustees of Columbia University in the City of New York | Dna sequencing with non-fluorescent nucleotide reversible terminators cleavable label modified nucleotide terminators |
US9309569B2 (en) | 2010-08-26 | 2016-04-12 | Intelligent Bio-Systems, Inc. | Methods and compositions for sequencing nucleic acid using charge |
ES2641871T3 (en) | 2010-12-17 | 2017-11-14 | The Trustees Of Columbia University In The City Of New York | DNA sequencing by synthesis using modified nucleotides and nanopore detection |
US9624539B2 (en) | 2011-05-23 | 2017-04-18 | The Trustees Of Columbia University In The City Of New York | DNA sequencing by synthesis using Raman and infrared spectroscopy detection |
EP2970356B1 (en) | 2013-03-15 | 2018-05-30 | Illumina Cambridge Limited | Modified nucleosides or nucleotides |
-
2001
- 2001-12-04 GB GBGB0129012.1A patent/GB0129012D0/en not_active Ceased
-
2008
- 2008-09-09 US US12/283,285 patent/US7772384B2/en not_active Expired - Lifetime
-
2010
- 2010-07-13 US US12/804,025 patent/US8158346B2/en not_active Expired - Fee Related
- 2010-07-19 US US12/804,296 patent/US8148064B2/en not_active Expired - Fee Related
-
2012
- 2012-03-28 US US13/432,989 patent/US8394586B2/en not_active Expired - Lifetime
- 2012-04-02 US US13/437,772 patent/US20120252010A1/en not_active Abandoned
-
2013
- 2013-03-08 US US13/791,597 patent/US9388463B2/en not_active Expired - Fee Related
- 2013-12-02 US US14/094,646 patent/US9121062B2/en not_active Expired - Fee Related
-
2015
- 2015-08-07 US US14/821,566 patent/US9605310B2/en not_active Expired - Lifetime
- 2015-09-17 US US14/857,671 patent/US9410200B2/en not_active Expired - Fee Related
-
2016
- 2016-07-05 US US15/202,456 patent/US10480025B2/en not_active Expired - Fee Related
- 2016-11-17 US US15/354,511 patent/US20170067104A1/en not_active Abandoned
-
2017
- 2017-03-27 US US15/470,801 patent/US10519496B2/en not_active Expired - Fee Related
-
2019
- 2019-10-04 US US16/593,512 patent/US20200109448A1/en not_active Abandoned
- 2019-12-23 US US16/726,040 patent/US20200115747A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11008359B2 (en) | 2002-08-23 | 2021-05-18 | Illumina Cambridge Limited | Labelled nucleotides |
US10995111B2 (en) | 2003-08-22 | 2021-05-04 | Illumina Cambridge Limited | Labelled nucleotides |
US11028116B2 (en) | 2003-08-22 | 2021-06-08 | Illumina Cambridge Limited | Labelled nucleotides |
US11028115B2 (en) | 2003-08-22 | 2021-06-08 | Illumina Cambridge Limited | Labelled nucleotides |
US10982277B2 (en) | 2013-03-15 | 2021-04-20 | Illumina Cambridge Limited | Modified nucleosides or nucleotides |
Also Published As
Publication number | Publication date |
---|---|
US20090170724A1 (en) | 2009-07-02 |
US20120202196A1 (en) | 2012-08-09 |
US9605310B2 (en) | 2017-03-28 |
US20100317531A1 (en) | 2010-12-16 |
GB0129012D0 (en) | 2002-01-23 |
US10480025B2 (en) | 2019-11-19 |
US9121062B2 (en) | 2015-09-01 |
US9410200B2 (en) | 2016-08-09 |
US20160002719A1 (en) | 2016-01-07 |
US20110183327A1 (en) | 2011-07-28 |
US8158346B2 (en) | 2012-04-17 |
US20170067104A1 (en) | 2017-03-09 |
US20200115747A1 (en) | 2020-04-16 |
US20140113282A1 (en) | 2014-04-24 |
US8394586B2 (en) | 2013-03-12 |
US7772384B2 (en) | 2010-08-10 |
US20170204458A1 (en) | 2017-07-20 |
US20130189743A1 (en) | 2013-07-25 |
US20160060692A1 (en) | 2016-03-03 |
US20120252010A1 (en) | 2012-10-04 |
US20170002407A1 (en) | 2017-01-05 |
US9388463B2 (en) | 2016-07-12 |
US8148064B2 (en) | 2012-04-03 |
US10519496B2 (en) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200109448A1 (en) | Labelled nucleotides | |
US7785796B2 (en) | Labelled nucleotides | |
EP3147292A1 (en) | Labelled nucleotides | |
US20060160081A1 (en) | Labelled nucleotides | |
US20210009623A1 (en) | Labelled nucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |